StudyID,Drug_Name,Arm_ID,Endpoint_Name,Endpoint_Type,Strategy,EP_P_value,Missing_Imput,Covariate_Adjust,MCP,Subgroup_Ana,EP_Value,EP_Unit,EP_Point,ARR,NNT,EP_95CI,Med_OS,OS_YrX,Med_PFS,ORR,pCR,Med_DOR,RMST,PRO,QoL,endpoint_group_id,endpoint_group_title_raw,endpoint_group_desc_raw,endpoint_group_title_norm,endpoint_group_desc_norm,matched_arm_id,arm_group_title_raw,arm_group_desc_raw,arm_group_title_norm,arm_group_desc_norm,match_type,title_score,desc_score,debug_notes,top_candidates_json
NCT01295827,Pembrolizumab,NCT01295827_A1,Number of Participants Experiencing Dose-Limiting Toxicities (DLTs) According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 (NCI-CTCAE v.4.0) in Participants With Solid Tumors (Parts A and A1),Primary,,[],,,,,"[{""measure_title"": ""Number of Participants Experiencing Dose-Limiting Toxicities (DLTs) According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 (NCI-CTCAE v.4.0) in Participants With Solid Tumors (Parts A and A1)"", ""units"": ""Participants"", ""param"": ""Number"", ""values"": [{""group_id"": ""O1"", ""value"": ""0""}]}]",Participants,[],,,[],,,,,,,,,,O1,Solid Tumors: Pembrolizumab 1 mg/kg Q2W (Part A),During Cycle 1 participants received a dose of 1 mg/kg pembrolizumab IV infusion over 30 minutes on Day 1 of a 28-day cycle for evaluation of dose-limiting toxicities and pharmacokinetics. Participants received pembrolizumab IV at a dose of 1 mg/kg Q2W starting with Cycle 2.,solid tumors pembrolizumab 1 mg kg q2w part a,during cycle 1 participants received a dose of 1 mg kg pembrolizumab iv infusion over 30 minutes on day 1 of a 28 day cycle for evaluation of dose limiting toxicities and pharmacokinetics participants received pembrolizumab iv at a dose of 1 mg kg q2w starting with cycle 2,NCT01295827_A1,Solid Tumors: Pembrolizumab 1 mg/kg Q2W (Part A),During Cycle 1 participants received a dose of 1 mg/kg pembrolizumab intravenous (IV) infusion over 30 minutes on Day 1 of a 28-day cycle for evaluation of dose-limiting toxicities and pharmacokinetics. Participants received pembrolizumab IV at a dose of 1 mg/kg every 2 weeks (Q2W) starting with Cycle 2.,solid tumors pembrolizumab 1 mg kg q2w part a,during cycle 1 participants received a dose of 1 mg kg pembrolizumab intravenous iv infusion over 30 minutes on day 1 of a 28 day cycle for evaluation of dose limiting toxicities and pharmacokinetics participants received pembrolizumab iv at a dose of 1 mg kg every 2 weeks q2w starting with cycle 2,precise_title,100,95,,"[{""arm_id"": ""NCT01295827_A3"", ""arm_group_title_raw"": ""Solid Tumors: Pembrolizumab 10 mg/kg Q2W (Parts A+A1)"", ""arm_group_desc_raw"": ""During Cycle 1 participants received a dose of 10 mg/kg pembrolizumab IV infusion over 30 minutes on Day 1 of a 28-day cycle for evaluation of dose-limiting toxicities and pharmacokinetics. Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W starting with Cycle 2."", ""title_score"": 95, ""desc_score"": 100}, {""arm_id"": ""NCT01295827_A2"", ""arm_group_title_raw"": ""Solid Tumors: Pembrolizumab 3 mg/kg Q2W (Part A)"", ""arm_group_desc_raw"": ""During Cycle 1 participants received a dose of 3 mg/kg pembrolizumab IV infusion over 30 minutes on Day 1 of a 28-day cycle for evaluation of dose-limiting toxicities and pharmacokinetics. Participants received pembrolizumab IV at a dose of 3 mg/kg Q2W starting with Cycle 2."", ""title_score"": 98, ""desc_score"": 99}, {""arm_id"": ""NCT01295827_A1"", ""arm_group_title_raw"": ""Solid Tumors: Pembrolizumab 1 mg/kg Q2W (Part A)"", ""arm_group_desc_raw"": ""During Cycle 1 participants received a dose of 1 mg/kg pembrolizumab intravenous (IV) infusion over 30 minutes on Day 1 of a 28-day cycle for evaluation of dose-limiting toxicities and pharmacokinetics. Participants received pembrolizumab IV at a dose of 1 mg/kg every 2 weeks (Q2W) starting with Cycle 2."", ""title_score"": 100, ""desc_score"": 95}]"
NCT01295827,Pembrolizumab,NCT01295827_A2,Number of Participants Experiencing Dose-Limiting Toxicities (DLTs) According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 (NCI-CTCAE v.4.0) in Participants With Solid Tumors (Parts A and A1),Primary,,[],,,,,"[{""measure_title"": ""Number of Participants Experiencing Dose-Limiting Toxicities (DLTs) According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 (NCI-CTCAE v.4.0) in Participants With Solid Tumors (Parts A and A1)"", ""units"": ""Participants"", ""param"": ""Number"", ""values"": [{""group_id"": ""O2"", ""value"": ""0""}]}]",Participants,[],,,[],,,,,,,,,,O2,Solid Tumors: Pembrolizumab 3 mg/kg Q2W (Part A),During Cycle 1 participants received a dose of 3 mg/kg pembrolizumab IV infusion over 30 minutes on Day 1 of a 28-day cycle for evaluation of dose-limiting toxicities and pharmacokinetics. Participants received pembrolizumab IV at a dose of 3 mg/kg Q2W starting with Cycle 2.,solid tumors pembrolizumab 3 mg kg q2w part a,during cycle 1 participants received a dose of 3 mg kg pembrolizumab iv infusion over 30 minutes on day 1 of a 28 day cycle for evaluation of dose limiting toxicities and pharmacokinetics participants received pembrolizumab iv at a dose of 3 mg kg q2w starting with cycle 2,NCT01295827_A2,Solid Tumors: Pembrolizumab 3 mg/kg Q2W (Part A),During Cycle 1 participants received a dose of 3 mg/kg pembrolizumab IV infusion over 30 minutes on Day 1 of a 28-day cycle for evaluation of dose-limiting toxicities and pharmacokinetics. Participants received pembrolizumab IV at a dose of 3 mg/kg Q2W starting with Cycle 2.,solid tumors pembrolizumab 3 mg kg q2w part a,during cycle 1 participants received a dose of 3 mg kg pembrolizumab iv infusion over 30 minutes on day 1 of a 28 day cycle for evaluation of dose limiting toxicities and pharmacokinetics participants received pembrolizumab iv at a dose of 3 mg kg q2w starting with cycle 2,precise_title,100,100,,"[{""arm_id"": ""NCT01295827_A2"", ""arm_group_title_raw"": ""Solid Tumors: Pembrolizumab 3 mg/kg Q2W (Part A)"", ""arm_group_desc_raw"": ""During Cycle 1 participants received a dose of 3 mg/kg pembrolizumab IV infusion over 30 minutes on Day 1 of a 28-day cycle for evaluation of dose-limiting toxicities and pharmacokinetics. Participants received pembrolizumab IV at a dose of 3 mg/kg Q2W starting with Cycle 2."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT01295827_A3"", ""arm_group_title_raw"": ""Solid Tumors: Pembrolizumab 10 mg/kg Q2W (Parts A+A1)"", ""arm_group_desc_raw"": ""During Cycle 1 participants received a dose of 10 mg/kg pembrolizumab IV infusion over 30 minutes on Day 1 of a 28-day cycle for evaluation of dose-limiting toxicities and pharmacokinetics. Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W starting with Cycle 2."", ""title_score"": 93, ""desc_score"": 99}, {""arm_id"": ""NCT01295827_A1"", ""arm_group_title_raw"": ""Solid Tumors: Pembrolizumab 1 mg/kg Q2W (Part A)"", ""arm_group_desc_raw"": ""During Cycle 1 participants received a dose of 1 mg/kg pembrolizumab intravenous (IV) infusion over 30 minutes on Day 1 of a 28-day cycle for evaluation of dose-limiting toxicities and pharmacokinetics. Participants received pembrolizumab IV at a dose of 1 mg/kg every 2 weeks (Q2W) starting with Cycle 2."", ""title_score"": 98, ""desc_score"": 93}]"
NCT01295827,Pembrolizumab,NCT01295827_A3,Number of Participants Experiencing Dose-Limiting Toxicities (DLTs) According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 (NCI-CTCAE v.4.0) in Participants With Solid Tumors (Parts A and A1),Primary,,[],,,,,"[{""measure_title"": ""Number of Participants Experiencing Dose-Limiting Toxicities (DLTs) According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 (NCI-CTCAE v.4.0) in Participants With Solid Tumors (Parts A and A1)"", ""units"": ""Participants"", ""param"": ""Number"", ""values"": [{""group_id"": ""O3"", ""value"": ""0""}]}]",Participants,[],,,[],,,,,,,,,,O3,Solid Tumors: Pembrolizumab 10 mg/kg Q2W (Parts A+A1),During Cycle 1 participants received a dose of 10 mg/kg pembrolizumab IV infusion over 30 minutes on Day 1 of a 28-day cycle for evaluation of dose-limiting toxicities and pharmacokinetics. Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W starting with Cycle 2.,solid tumors pembrolizumab 10 mg kg q2w parts a a1,during cycle 1 participants received a dose of 10 mg kg pembrolizumab iv infusion over 30 minutes on day 1 of a 28 day cycle for evaluation of dose limiting toxicities and pharmacokinetics participants received pembrolizumab iv at a dose of 10 mg kg q2w starting with cycle 2,NCT01295827_A3,Solid Tumors: Pembrolizumab 10 mg/kg Q2W (Parts A+A1),During Cycle 1 participants received a dose of 10 mg/kg pembrolizumab IV infusion over 30 minutes on Day 1 of a 28-day cycle for evaluation of dose-limiting toxicities and pharmacokinetics. Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W starting with Cycle 2.,solid tumors pembrolizumab 10 mg kg q2w parts a a1,during cycle 1 participants received a dose of 10 mg kg pembrolizumab iv infusion over 30 minutes on day 1 of a 28 day cycle for evaluation of dose limiting toxicities and pharmacokinetics participants received pembrolizumab iv at a dose of 10 mg kg q2w starting with cycle 2,precise_title,100,100,,"[{""arm_id"": ""NCT01295827_A3"", ""arm_group_title_raw"": ""Solid Tumors: Pembrolizumab 10 mg/kg Q2W (Parts A+A1)"", ""arm_group_desc_raw"": ""During Cycle 1 participants received a dose of 10 mg/kg pembrolizumab IV infusion over 30 minutes on Day 1 of a 28-day cycle for evaluation of dose-limiting toxicities and pharmacokinetics. Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W starting with Cycle 2."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT01295827_A2"", ""arm_group_title_raw"": ""Solid Tumors: Pembrolizumab 3 mg/kg Q2W (Part A)"", ""arm_group_desc_raw"": ""During Cycle 1 participants received a dose of 3 mg/kg pembrolizumab IV infusion over 30 minutes on Day 1 of a 28-day cycle for evaluation of dose-limiting toxicities and pharmacokinetics. Participants received pembrolizumab IV at a dose of 3 mg/kg Q2W starting with Cycle 2."", ""title_score"": 93, ""desc_score"": 99}, {""arm_id"": ""NCT01295827_A1"", ""arm_group_title_raw"": ""Solid Tumors: Pembrolizumab 1 mg/kg Q2W (Part A)"", ""arm_group_desc_raw"": ""During Cycle 1 participants received a dose of 1 mg/kg pembrolizumab intravenous (IV) infusion over 30 minutes on Day 1 of a 28-day cycle for evaluation of dose-limiting toxicities and pharmacokinetics. Participants received pembrolizumab IV at a dose of 1 mg/kg every 2 weeks (Q2W) starting with Cycle 2."", ""title_score"": 95, ""desc_score"": 93}]"
NCT01295827,Pembrolizumab,NCT01295827_A4,Number of Participants Experiencing Dose-Limiting Toxicities (DLTs) According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 (NCI-CTCAE v.4.0) in Participants With Solid Tumors (Parts A and A1),Primary,,[],,,,,[],,[],,,[],,,,,,,,,,O4,Solid Tumors: Pembrolizumab Titration Cohort 1 Q3W (Part A2),"During Cycle 1 participants received pembrolizumab dose titration from 0.005 mg/kg to 0.3 mg/kg to 2.0 mg/kg on Days 1, 8, and 22, administered as an IV infusion over 30 minutes. Participants received 2 mg/kg every 3 weeks (Q3W) starting with Cycle 2.",solid tumors pembrolizumab titration cohort 1 q3w part a2,during cycle 1 participants received pembrolizumab dose titration from 0 005 mg kg to 0 3 mg kg to 2 0 mg kg on days 1 8 and 22 administered as an iv infusion over 30 minutes participants received 2 mg kg every 3 weeks q3w starting with cycle 2,NCT01295827_A4,Solid Tumors: Pembrolizumab Titration Cohort 1 Q3W (Part A2),"During Cycle 1 participants received pembrolizumab dose titration from 0.005 mg/kg to 0.3 mg/kg to 2.0 mg/kg on Days 1, 8, and 22, administered as an IV infusion over 30 minutes. Participants received 2 mg/kg every 3 weeks (Q3W) starting with Cycle 2.",solid tumors pembrolizumab titration cohort 1 q3w part a2,during cycle 1 participants received pembrolizumab dose titration from 0 005 mg kg to 0 3 mg kg to 2 0 mg kg on days 1 8 and 22 administered as an iv infusion over 30 minutes participants received 2 mg kg every 3 weeks q3w starting with cycle 2,precise_title,100,100,,"[{""arm_id"": ""NCT01295827_A4"", ""arm_group_title_raw"": ""Solid Tumors: Pembrolizumab Titration Cohort 1 Q3W (Part A2)"", ""arm_group_desc_raw"": ""During Cycle 1 participants received pembrolizumab dose titration from 0.005 mg/kg to 0.3 mg/kg to 2.0 mg/kg on Days 1, 8, and 22, administered as an IV infusion over 30 minutes. Participants received 2 mg/kg every 3 weeks (Q3W) starting with Cycle 2."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT01295827_A5"", ""arm_group_title_raw"": ""Solid Tumors: Pembrolizumab Titration Cohort 2 Q3W (Part A2)"", ""arm_group_desc_raw"": ""During Cycle 1 participants received pembrolizumab dose titration from 0.02 mg/kg to 0.3 mg/kg to 2.0 mg/kg on Days 1, 8, and 22, administered as an IV infusion over 30 minutes. Participants received 2 mg/kg Q3W starting with Cycle 2."", ""title_score"": 98, ""desc_score"": 96}, {""arm_id"": ""NCT01295827_A6"", ""arm_group_title_raw"": ""Solid Tumors: Pembrolizumab Titration Cohort 3 Q3W (Part A2)"", ""arm_group_desc_raw"": ""During Cycle 1 participants received pembrolizumab dose titration from 0.06 mg/kg to 1.0 mg/kg to 10 mg/kg on Days 1, 8, and 22, administered as an IV infusion over 30 minutes. Participants received 10 mg/kg Q3W starting with Cycle 2."", ""title_score"": 98, ""desc_score"": 83}]"
NCT01295827,Pembrolizumab,NCT01295827_A5,Number of Participants Experiencing Dose-Limiting Toxicities (DLTs) According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 (NCI-CTCAE v.4.0) in Participants With Solid Tumors (Parts A and A1),Primary,,[],,,,,[],,[],,,[],,,,,,,,,,O5,Solid Tumors: Pembrolizumab Titration Cohort 2 Q3W (Part A2),"During Cycle 1 participants received pembrolizumab dose titration from 0.02 mg/kg to 0.3 mg/kg to 2.0 mg/kg on Days 1, 8, and 22, administered as an IV infusion over 30 minutes. Participants received 2 mg/kg Q3W starting with Cycle 2.",solid tumors pembrolizumab titration cohort 2 q3w part a2,during cycle 1 participants received pembrolizumab dose titration from 0 02 mg kg to 0 3 mg kg to 2 0 mg kg on days 1 8 and 22 administered as an iv infusion over 30 minutes participants received 2 mg kg q3w starting with cycle 2,NCT01295827_A5,Solid Tumors: Pembrolizumab Titration Cohort 2 Q3W (Part A2),"During Cycle 1 participants received pembrolizumab dose titration from 0.02 mg/kg to 0.3 mg/kg to 2.0 mg/kg on Days 1, 8, and 22, administered as an IV infusion over 30 minutes. Participants received 2 mg/kg Q3W starting with Cycle 2.",solid tumors pembrolizumab titration cohort 2 q3w part a2,during cycle 1 participants received pembrolizumab dose titration from 0 02 mg kg to 0 3 mg kg to 2 0 mg kg on days 1 8 and 22 administered as an iv infusion over 30 minutes participants received 2 mg kg q3w starting with cycle 2,precise_title,100,100,,"[{""arm_id"": ""NCT01295827_A5"", ""arm_group_title_raw"": ""Solid Tumors: Pembrolizumab Titration Cohort 2 Q3W (Part A2)"", ""arm_group_desc_raw"": ""During Cycle 1 participants received pembrolizumab dose titration from 0.02 mg/kg to 0.3 mg/kg to 2.0 mg/kg on Days 1, 8, and 22, administered as an IV infusion over 30 minutes. Participants received 2 mg/kg Q3W starting with Cycle 2."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT01295827_A4"", ""arm_group_title_raw"": ""Solid Tumors: Pembrolizumab Titration Cohort 1 Q3W (Part A2)"", ""arm_group_desc_raw"": ""During Cycle 1 participants received pembrolizumab dose titration from 0.005 mg/kg to 0.3 mg/kg to 2.0 mg/kg on Days 1, 8, and 22, administered as an IV infusion over 30 minutes. Participants received 2 mg/kg every 3 weeks (Q3W) starting with Cycle 2."", ""title_score"": 98, ""desc_score"": 96}, {""arm_id"": ""NCT01295827_A6"", ""arm_group_title_raw"": ""Solid Tumors: Pembrolizumab Titration Cohort 3 Q3W (Part A2)"", ""arm_group_desc_raw"": ""During Cycle 1 participants received pembrolizumab dose titration from 0.06 mg/kg to 1.0 mg/kg to 10 mg/kg on Days 1, 8, and 22, administered as an IV infusion over 30 minutes. Participants received 10 mg/kg Q3W starting with Cycle 2."", ""title_score"": 98, ""desc_score"": 88}]"
NCT01295827,Pembrolizumab,NCT01295827_A6,Number of Participants Experiencing Dose-Limiting Toxicities (DLTs) According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 (NCI-CTCAE v.4.0) in Participants With Solid Tumors (Parts A and A1),Primary,,[],,,,,[],,[],,,[],,,,,,,,,,O6,Solid Tumors: Pembrolizumab Titration Cohort 3 Q3W (Part A2),"During Cycle 1 participants received pembrolizumab dose titration from 0.06 mg/kg to 1.0 mg/kg to 10 mg/kg on Days 1, 8, and 22, administered as an IV infusion over 30 minutes. Participants received 10 mg/kg Q3W starting with Cycle 2.",solid tumors pembrolizumab titration cohort 3 q3w part a2,during cycle 1 participants received pembrolizumab dose titration from 0 06 mg kg to 1 0 mg kg to 10 mg kg on days 1 8 and 22 administered as an iv infusion over 30 minutes participants received 10 mg kg q3w starting with cycle 2,NCT01295827_A6,Solid Tumors: Pembrolizumab Titration Cohort 3 Q3W (Part A2),"During Cycle 1 participants received pembrolizumab dose titration from 0.06 mg/kg to 1.0 mg/kg to 10 mg/kg on Days 1, 8, and 22, administered as an IV infusion over 30 minutes. Participants received 10 mg/kg Q3W starting with Cycle 2.",solid tumors pembrolizumab titration cohort 3 q3w part a2,during cycle 1 participants received pembrolizumab dose titration from 0 06 mg kg to 1 0 mg kg to 10 mg kg on days 1 8 and 22 administered as an iv infusion over 30 minutes participants received 10 mg kg q3w starting with cycle 2,precise_title,100,100,,"[{""arm_id"": ""NCT01295827_A6"", ""arm_group_title_raw"": ""Solid Tumors: Pembrolizumab Titration Cohort 3 Q3W (Part A2)"", ""arm_group_desc_raw"": ""During Cycle 1 participants received pembrolizumab dose titration from 0.06 mg/kg to 1.0 mg/kg to 10 mg/kg on Days 1, 8, and 22, administered as an IV infusion over 30 minutes. Participants received 10 mg/kg Q3W starting with Cycle 2."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT01295827_A5"", ""arm_group_title_raw"": ""Solid Tumors: Pembrolizumab Titration Cohort 2 Q3W (Part A2)"", ""arm_group_desc_raw"": ""During Cycle 1 participants received pembrolizumab dose titration from 0.02 mg/kg to 0.3 mg/kg to 2.0 mg/kg on Days 1, 8, and 22, administered as an IV infusion over 30 minutes. Participants received 2 mg/kg Q3W starting with Cycle 2."", ""title_score"": 98, ""desc_score"": 82}, {""arm_id"": ""NCT01295827_A4"", ""arm_group_title_raw"": ""Solid Tumors: Pembrolizumab Titration Cohort 1 Q3W (Part A2)"", ""arm_group_desc_raw"": ""During Cycle 1 participants received pembrolizumab dose titration from 0.005 mg/kg to 0.3 mg/kg to 2.0 mg/kg on Days 1, 8, and 22, administered as an IV infusion over 30 minutes. Participants received 2 mg/kg every 3 weeks (Q3W) starting with Cycle 2."", ""title_score"": 98, ""desc_score"": 77}]"
NCT01295827,Pembrolizumab,NCT01295827_A7,Number of Participants Experiencing Dose-Limiting Toxicities (DLTs) According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 (NCI-CTCAE v.4.0) in Participants With Solid Tumors (Parts A and A1),Primary,,[],,,,,[],,[],,,[],,,,,,,,,,O7,MEL: Pembrolizumab 2 mg/kg Q3W (Parts B+D),"Participants received pembrolizumab IV at a dose of 2 mg/kg Q2W. After Amendment 3, participants received dosing Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data.",mel pembrolizumab 2 mg kg q3w parts b d,participants received pembrolizumab iv at a dose of 2 mg kg q2w after amendment 3 participants received dosing q3w after amendment 10 all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab iv q3w based on analysis of safety and efficacy data,NCT01295827_A7,MEL: Pembrolizumab 2 mg/kg Q3W (Parts B+D),"Participants received pembrolizumab IV at a dose of 2 mg/kg Q2W. After Amendment 3, participants received dosing Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data.",mel pembrolizumab 2 mg kg q3w parts b d,participants received pembrolizumab iv at a dose of 2 mg kg q2w after amendment 3 participants received dosing q3w after amendment 10 all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab iv q3w based on analysis of safety and efficacy data,precise_title,100,100,,"[{""arm_id"": ""NCT01295827_A7"", ""arm_group_title_raw"": ""MEL: Pembrolizumab 2 mg/kg Q3W (Parts B+D)"", ""arm_group_desc_raw"": ""Participants received pembrolizumab IV at a dose of 2 mg/kg Q2W. After Amendment 3, participants received dosing Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT01295827_A8"", ""arm_group_title_raw"": ""MEL: Pembrolizumab 10 mg/kg Q3W (Parts B+D)"", ""arm_group_desc_raw"": ""Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W. After Amendment 7, participants received dosing Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data."", ""title_score"": 96, ""desc_score"": 99}, {""arm_id"": ""NCT01295827_A10"", ""arm_group_title_raw"": ""NSCLC: Pembrolizumab 2 mg/kg Q3W (Part F)"", ""arm_group_desc_raw"": ""Participants received pembrolizumab IV at a dose of 2 mg/kg Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data."", ""title_score"": 86, ""desc_score"": 90}]"
NCT01295827,Pembrolizumab,NCT01295827_A8,Number of Participants Experiencing Dose-Limiting Toxicities (DLTs) According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 (NCI-CTCAE v.4.0) in Participants With Solid Tumors (Parts A and A1),Primary,,[],,,,,[],,[],,,[],,,,,,,,,,O8,MEL: Pembrolizumab 10 mg/kg Q3W (Parts B+D),"Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W. After Amendment 7, participants received dosing Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data.",mel pembrolizumab 10 mg kg q3w parts b d,participants received pembrolizumab iv at a dose of 10 mg kg q2w after amendment 7 participants received dosing q3w after amendment 10 all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab iv q3w based on analysis of safety and efficacy data,NCT01295827_A8,MEL: Pembrolizumab 10 mg/kg Q3W (Parts B+D),"Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W. After Amendment 7, participants received dosing Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data.",mel pembrolizumab 10 mg kg q3w parts b d,participants received pembrolizumab iv at a dose of 10 mg kg q2w after amendment 7 participants received dosing q3w after amendment 10 all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab iv q3w based on analysis of safety and efficacy data,precise_title,100,100,,"[{""arm_id"": ""NCT01295827_A8"", ""arm_group_title_raw"": ""MEL: Pembrolizumab 10 mg/kg Q3W (Parts B+D)"", ""arm_group_desc_raw"": ""Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W. After Amendment 7, participants received dosing Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT01295827_A7"", ""arm_group_title_raw"": ""MEL: Pembrolizumab 2 mg/kg Q3W (Parts B+D)"", ""arm_group_desc_raw"": ""Participants received pembrolizumab IV at a dose of 2 mg/kg Q2W. After Amendment 3, participants received dosing Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data."", ""title_score"": 96, ""desc_score"": 99}, {""arm_id"": ""NCT01295827_A10"", ""arm_group_title_raw"": ""NSCLC: Pembrolizumab 2 mg/kg Q3W (Part F)"", ""arm_group_desc_raw"": ""Participants received pembrolizumab IV at a dose of 2 mg/kg Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data."", ""title_score"": 82, ""desc_score"": 89}]"
NCT01295827,Pembrolizumab,NCT01295827_A9,Number of Participants Experiencing Dose-Limiting Toxicities (DLTs) According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 (NCI-CTCAE v.4.0) in Participants With Solid Tumors (Parts A and A1),Primary,,[],,,,,[],,[],,,[],,,,,,,,,,O9,MEL: Pembrolizumab 10 mg/kg Q2W (Part B),"Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data.",mel pembrolizumab 10 mg kg q2w part b,participants received pembrolizumab iv at a dose of 10 mg kg q2w after amendment 10 all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab iv q3w based on analysis of safety and efficacy data,NCT01295827_A9,MEL: Pembrolizumab 10 mg/kg Q2W (Part B),"Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data.",mel pembrolizumab 10 mg kg q2w part b,participants received pembrolizumab iv at a dose of 10 mg kg q2w after amendment 10 all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab iv q3w based on analysis of safety and efficacy data,precise_title,100,100,,"[{""arm_id"": ""NCT01295827_A9"", ""arm_group_title_raw"": ""MEL: Pembrolizumab 10 mg/kg Q2W (Part B)"", ""arm_group_desc_raw"": ""Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT01295827_A12"", ""arm_group_title_raw"": ""NSCLC: Pembrolizumab 10 mg/kg Q2W (Part F)"", ""arm_group_desc_raw"": ""Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data."", ""title_score"": 89, ""desc_score"": 100}, {""arm_id"": ""NCT01295827_A11"", ""arm_group_title_raw"": ""NSCLC: Pembrolizumab 10 mg/kg Q3W (Parts C+F)"", ""arm_group_desc_raw"": ""Participants received pembrolizumab IV at a dose of 10 mg/kg Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data."", ""title_score"": 84, ""desc_score"": 100}]"
NCT01295827,Pembrolizumab,NCT01295827_A10,Number of Participants Experiencing Dose-Limiting Toxicities (DLTs) According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 (NCI-CTCAE v.4.0) in Participants With Solid Tumors (Parts A and A1),Primary,,[],,,,,[],,[],,,[],,,,,,,,,,O10,NSCLC: Pembrolizumab 2 mg/kg Q3W (Part F),"Participants received pembrolizumab IV at a dose of 2 mg/kg Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data.",nsclc pembrolizumab 2 mg kg q3w part f,participants received pembrolizumab iv at a dose of 2 mg kg q3w after amendment 10 all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab iv q3w based on analysis of safety and efficacy data,NCT01295827_A10,NSCLC: Pembrolizumab 2 mg/kg Q3W (Part F),"Participants received pembrolizumab IV at a dose of 2 mg/kg Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data.",nsclc pembrolizumab 2 mg kg q3w part f,participants received pembrolizumab iv at a dose of 2 mg kg q3w after amendment 10 all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab iv q3w based on analysis of safety and efficacy data,precise_title,100,100,,"[{""arm_id"": ""NCT01295827_A10"", ""arm_group_title_raw"": ""NSCLC: Pembrolizumab 2 mg/kg Q3W (Part F)"", ""arm_group_desc_raw"": ""Participants received pembrolizumab IV at a dose of 2 mg/kg Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT01295827_A11"", ""arm_group_title_raw"": ""NSCLC: Pembrolizumab 10 mg/kg Q3W (Parts C+F)"", ""arm_group_desc_raw"": ""Participants received pembrolizumab IV at a dose of 10 mg/kg Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data."", ""title_score"": 92, ""desc_score"": 99}, {""arm_id"": ""NCT01295827_A7"", ""arm_group_title_raw"": ""MEL: Pembrolizumab 2 mg/kg Q3W (Parts B+D)"", ""arm_group_desc_raw"": ""Participants received pembrolizumab IV at a dose of 2 mg/kg Q2W. After Amendment 3, participants received dosing Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data."", ""title_score"": 86, ""desc_score"": 90}]"
NCT01295827,Pembrolizumab,NCT01295827_A11,Number of Participants Experiencing Dose-Limiting Toxicities (DLTs) According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 (NCI-CTCAE v.4.0) in Participants With Solid Tumors (Parts A and A1),Primary,,[],,,,,[],,[],,,[],,,,,,,,,,O11,NSCLC: Pembrolizumab 10 mg/kg Q3W (Parts C+F),"Participants received pembrolizumab IV at a dose of 10 mg/kg Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data.",nsclc pembrolizumab 10 mg kg q3w parts c f,participants received pembrolizumab iv at a dose of 10 mg kg q3w after amendment 10 all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab iv q3w based on analysis of safety and efficacy data,NCT01295827_A11,NSCLC: Pembrolizumab 10 mg/kg Q3W (Parts C+F),"Participants received pembrolizumab IV at a dose of 10 mg/kg Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data.",nsclc pembrolizumab 10 mg kg q3w parts c f,participants received pembrolizumab iv at a dose of 10 mg kg q3w after amendment 10 all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab iv q3w based on analysis of safety and efficacy data,precise_title,100,100,,"[{""arm_id"": ""NCT01295827_A11"", ""arm_group_title_raw"": ""NSCLC: Pembrolizumab 10 mg/kg Q3W (Parts C+F)"", ""arm_group_desc_raw"": ""Participants received pembrolizumab IV at a dose of 10 mg/kg Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT01295827_A12"", ""arm_group_title_raw"": ""NSCLC: Pembrolizumab 10 mg/kg Q2W (Part F)"", ""arm_group_desc_raw"": ""Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data."", ""title_score"": 94, ""desc_score"": 100}, {""arm_id"": ""NCT01295827_A9"", ""arm_group_title_raw"": ""MEL: Pembrolizumab 10 mg/kg Q2W (Part B)"", ""arm_group_desc_raw"": ""Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data."", ""title_score"": 84, ""desc_score"": 100}]"
NCT01295827,Pembrolizumab,NCT01295827_A12,Number of Participants Experiencing Dose-Limiting Toxicities (DLTs) According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 (NCI-CTCAE v.4.0) in Participants With Solid Tumors (Parts A and A1),Primary,,[],,,,,[],,[],,,[],,,,,,,,,,O12,NSCLC: Pembrolizumab 10 mg/kg Q2W (Part F),"Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data.",nsclc pembrolizumab 10 mg kg q2w part f,participants received pembrolizumab iv at a dose of 10 mg kg q2w after amendment 10 all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab iv q3w based on analysis of safety and efficacy data,NCT01295827_A12,NSCLC: Pembrolizumab 10 mg/kg Q2W (Part F),"Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data.",nsclc pembrolizumab 10 mg kg q2w part f,participants received pembrolizumab iv at a dose of 10 mg kg q2w after amendment 10 all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab iv q3w based on analysis of safety and efficacy data,precise_title,100,100,,"[{""arm_id"": ""NCT01295827_A12"", ""arm_group_title_raw"": ""NSCLC: Pembrolizumab 10 mg/kg Q2W (Part F)"", ""arm_group_desc_raw"": ""Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT01295827_A11"", ""arm_group_title_raw"": ""NSCLC: Pembrolizumab 10 mg/kg Q3W (Parts C+F)"", ""arm_group_desc_raw"": ""Participants received pembrolizumab IV at a dose of 10 mg/kg Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data."", ""title_score"": 94, ""desc_score"": 100}, {""arm_id"": ""NCT01295827_A9"", ""arm_group_title_raw"": ""MEL: Pembrolizumab 10 mg/kg Q2W (Part B)"", ""arm_group_desc_raw"": ""Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data."", ""title_score"": 89, ""desc_score"": 100}]"
NCT01295827,Pembrolizumab,NCT01295827_A1,Number of Participants Who Experienced an Adverse Event (AE),Primary,,[],,,,,"[{""measure_title"": ""Number of Participants Who Experienced an Adverse Event (AE)"", ""units"": ""Participants"", ""param"": ""Number"", ""values"": [{""group_id"": ""O1"", ""value"": ""4""}]}]",Participants,[],,,[],,,,,,,,,,O1,Solid Tumors: Pembrolizumab 1 mg/kg Q2W (Part A),During Cycle 1 participants received a dose of 1 mg/kg pembrolizumab IV infusion over 30 minutes on Day 1 of a 28-day cycle for evaluation of dose-limiting toxicities and pharmacokinetics. Participants received pembrolizumab IV at a dose of 1 mg/kg Q2W starting with Cycle 2.,solid tumors pembrolizumab 1 mg kg q2w part a,during cycle 1 participants received a dose of 1 mg kg pembrolizumab iv infusion over 30 minutes on day 1 of a 28 day cycle for evaluation of dose limiting toxicities and pharmacokinetics participants received pembrolizumab iv at a dose of 1 mg kg q2w starting with cycle 2,NCT01295827_A1,Solid Tumors: Pembrolizumab 1 mg/kg Q2W (Part A),During Cycle 1 participants received a dose of 1 mg/kg pembrolizumab intravenous (IV) infusion over 30 minutes on Day 1 of a 28-day cycle for evaluation of dose-limiting toxicities and pharmacokinetics. Participants received pembrolizumab IV at a dose of 1 mg/kg every 2 weeks (Q2W) starting with Cycle 2.,solid tumors pembrolizumab 1 mg kg q2w part a,during cycle 1 participants received a dose of 1 mg kg pembrolizumab intravenous iv infusion over 30 minutes on day 1 of a 28 day cycle for evaluation of dose limiting toxicities and pharmacokinetics participants received pembrolizumab iv at a dose of 1 mg kg every 2 weeks q2w starting with cycle 2,precise_title,100,95,,"[{""arm_id"": ""NCT01295827_A3"", ""arm_group_title_raw"": ""Solid Tumors: Pembrolizumab 10 mg/kg Q2W (Parts A+A1)"", ""arm_group_desc_raw"": ""During Cycle 1 participants received a dose of 10 mg/kg pembrolizumab IV infusion over 30 minutes on Day 1 of a 28-day cycle for evaluation of dose-limiting toxicities and pharmacokinetics. Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W starting with Cycle 2."", ""title_score"": 95, ""desc_score"": 100}, {""arm_id"": ""NCT01295827_A2"", ""arm_group_title_raw"": ""Solid Tumors: Pembrolizumab 3 mg/kg Q2W (Part A)"", ""arm_group_desc_raw"": ""During Cycle 1 participants received a dose of 3 mg/kg pembrolizumab IV infusion over 30 minutes on Day 1 of a 28-day cycle for evaluation of dose-limiting toxicities and pharmacokinetics. Participants received pembrolizumab IV at a dose of 3 mg/kg Q2W starting with Cycle 2."", ""title_score"": 98, ""desc_score"": 99}, {""arm_id"": ""NCT01295827_A1"", ""arm_group_title_raw"": ""Solid Tumors: Pembrolizumab 1 mg/kg Q2W (Part A)"", ""arm_group_desc_raw"": ""During Cycle 1 participants received a dose of 1 mg/kg pembrolizumab intravenous (IV) infusion over 30 minutes on Day 1 of a 28-day cycle for evaluation of dose-limiting toxicities and pharmacokinetics. Participants received pembrolizumab IV at a dose of 1 mg/kg every 2 weeks (Q2W) starting with Cycle 2."", ""title_score"": 100, ""desc_score"": 95}]"
NCT01295827,Pembrolizumab,NCT01295827_A2,Number of Participants Who Experienced an Adverse Event (AE),Primary,,[],,,,,"[{""measure_title"": ""Number of Participants Who Experienced an Adverse Event (AE)"", ""units"": ""Participants"", ""param"": ""Number"", ""values"": [{""group_id"": ""O2"", ""value"": ""3""}]}]",Participants,[],,,[],,,,,,,,,,O2,Solid Tumors: Pembrolizumab 3 mg/kg Q2W (Part A),During Cycle 1 participants received a dose of 3 mg/kg pembrolizumab IV infusion over 30 minutes on Day 1 of a 28-day cycle for evaluation of dose-limiting toxicities and pharmacokinetics. Participants received pembrolizumab IV at a dose of 3 mg/kg Q2W starting with Cycle 2.,solid tumors pembrolizumab 3 mg kg q2w part a,during cycle 1 participants received a dose of 3 mg kg pembrolizumab iv infusion over 30 minutes on day 1 of a 28 day cycle for evaluation of dose limiting toxicities and pharmacokinetics participants received pembrolizumab iv at a dose of 3 mg kg q2w starting with cycle 2,NCT01295827_A2,Solid Tumors: Pembrolizumab 3 mg/kg Q2W (Part A),During Cycle 1 participants received a dose of 3 mg/kg pembrolizumab IV infusion over 30 minutes on Day 1 of a 28-day cycle for evaluation of dose-limiting toxicities and pharmacokinetics. Participants received pembrolizumab IV at a dose of 3 mg/kg Q2W starting with Cycle 2.,solid tumors pembrolizumab 3 mg kg q2w part a,during cycle 1 participants received a dose of 3 mg kg pembrolizumab iv infusion over 30 minutes on day 1 of a 28 day cycle for evaluation of dose limiting toxicities and pharmacokinetics participants received pembrolizumab iv at a dose of 3 mg kg q2w starting with cycle 2,precise_title,100,100,,"[{""arm_id"": ""NCT01295827_A2"", ""arm_group_title_raw"": ""Solid Tumors: Pembrolizumab 3 mg/kg Q2W (Part A)"", ""arm_group_desc_raw"": ""During Cycle 1 participants received a dose of 3 mg/kg pembrolizumab IV infusion over 30 minutes on Day 1 of a 28-day cycle for evaluation of dose-limiting toxicities and pharmacokinetics. Participants received pembrolizumab IV at a dose of 3 mg/kg Q2W starting with Cycle 2."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT01295827_A3"", ""arm_group_title_raw"": ""Solid Tumors: Pembrolizumab 10 mg/kg Q2W (Parts A+A1)"", ""arm_group_desc_raw"": ""During Cycle 1 participants received a dose of 10 mg/kg pembrolizumab IV infusion over 30 minutes on Day 1 of a 28-day cycle for evaluation of dose-limiting toxicities and pharmacokinetics. Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W starting with Cycle 2."", ""title_score"": 93, ""desc_score"": 99}, {""arm_id"": ""NCT01295827_A1"", ""arm_group_title_raw"": ""Solid Tumors: Pembrolizumab 1 mg/kg Q2W (Part A)"", ""arm_group_desc_raw"": ""During Cycle 1 participants received a dose of 1 mg/kg pembrolizumab intravenous (IV) infusion over 30 minutes on Day 1 of a 28-day cycle for evaluation of dose-limiting toxicities and pharmacokinetics. Participants received pembrolizumab IV at a dose of 1 mg/kg every 2 weeks (Q2W) starting with Cycle 2."", ""title_score"": 98, ""desc_score"": 93}]"
NCT01295827,Pembrolizumab,NCT01295827_A3,Number of Participants Who Experienced an Adverse Event (AE),Primary,,[],,,,,"[{""measure_title"": ""Number of Participants Who Experienced an Adverse Event (AE)"", ""units"": ""Participants"", ""param"": ""Number"", ""values"": [{""group_id"": ""O3"", ""value"": ""9""}]}]",Participants,[],,,[],,,,,,,,,,O3,Solid Tumors: Pembrolizumab 10 mg/kg Q2W (Parts A+A1),During Cycle 1 participants received a dose of 10 mg/kg pembrolizumab IV infusion over 30 minutes on Day 1 of a 28-day cycle for evaluation of dose-limiting toxicities and pharmacokinetics. Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W starting with Cycle 2.,solid tumors pembrolizumab 10 mg kg q2w parts a a1,during cycle 1 participants received a dose of 10 mg kg pembrolizumab iv infusion over 30 minutes on day 1 of a 28 day cycle for evaluation of dose limiting toxicities and pharmacokinetics participants received pembrolizumab iv at a dose of 10 mg kg q2w starting with cycle 2,NCT01295827_A3,Solid Tumors: Pembrolizumab 10 mg/kg Q2W (Parts A+A1),During Cycle 1 participants received a dose of 10 mg/kg pembrolizumab IV infusion over 30 minutes on Day 1 of a 28-day cycle for evaluation of dose-limiting toxicities and pharmacokinetics. Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W starting with Cycle 2.,solid tumors pembrolizumab 10 mg kg q2w parts a a1,during cycle 1 participants received a dose of 10 mg kg pembrolizumab iv infusion over 30 minutes on day 1 of a 28 day cycle for evaluation of dose limiting toxicities and pharmacokinetics participants received pembrolizumab iv at a dose of 10 mg kg q2w starting with cycle 2,precise_title,100,100,,"[{""arm_id"": ""NCT01295827_A3"", ""arm_group_title_raw"": ""Solid Tumors: Pembrolizumab 10 mg/kg Q2W (Parts A+A1)"", ""arm_group_desc_raw"": ""During Cycle 1 participants received a dose of 10 mg/kg pembrolizumab IV infusion over 30 minutes on Day 1 of a 28-day cycle for evaluation of dose-limiting toxicities and pharmacokinetics. Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W starting with Cycle 2."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT01295827_A2"", ""arm_group_title_raw"": ""Solid Tumors: Pembrolizumab 3 mg/kg Q2W (Part A)"", ""arm_group_desc_raw"": ""During Cycle 1 participants received a dose of 3 mg/kg pembrolizumab IV infusion over 30 minutes on Day 1 of a 28-day cycle for evaluation of dose-limiting toxicities and pharmacokinetics. Participants received pembrolizumab IV at a dose of 3 mg/kg Q2W starting with Cycle 2."", ""title_score"": 93, ""desc_score"": 99}, {""arm_id"": ""NCT01295827_A1"", ""arm_group_title_raw"": ""Solid Tumors: Pembrolizumab 1 mg/kg Q2W (Part A)"", ""arm_group_desc_raw"": ""During Cycle 1 participants received a dose of 1 mg/kg pembrolizumab intravenous (IV) infusion over 30 minutes on Day 1 of a 28-day cycle for evaluation of dose-limiting toxicities and pharmacokinetics. Participants received pembrolizumab IV at a dose of 1 mg/kg every 2 weeks (Q2W) starting with Cycle 2."", ""title_score"": 95, ""desc_score"": 93}]"
NCT01295827,Pembrolizumab,NCT01295827_A4,Number of Participants Who Experienced an Adverse Event (AE),Primary,,[],,,,,"[{""measure_title"": ""Number of Participants Who Experienced an Adverse Event (AE)"", ""units"": ""Participants"", ""param"": ""Number"", ""values"": [{""group_id"": ""O4"", ""value"": ""4""}]}]",Participants,[],,,[],,,,,,,,,,O4,Solid Tumors: Pembrolizumab Titration Cohort 1 Q3W (Part A2),"During Cycle 1 participants received pembrolizumab dose titration from 0.005 mg/kg to 0.3 mg/kg to 2.0 mg/kg on Days 1, 8, and 22, administered as an IV infusion over 30 minutes. Participants received 2 mg/kg every 3 weeks (Q3W) starting with Cycle 2.",solid tumors pembrolizumab titration cohort 1 q3w part a2,during cycle 1 participants received pembrolizumab dose titration from 0 005 mg kg to 0 3 mg kg to 2 0 mg kg on days 1 8 and 22 administered as an iv infusion over 30 minutes participants received 2 mg kg every 3 weeks q3w starting with cycle 2,NCT01295827_A4,Solid Tumors: Pembrolizumab Titration Cohort 1 Q3W (Part A2),"During Cycle 1 participants received pembrolizumab dose titration from 0.005 mg/kg to 0.3 mg/kg to 2.0 mg/kg on Days 1, 8, and 22, administered as an IV infusion over 30 minutes. Participants received 2 mg/kg every 3 weeks (Q3W) starting with Cycle 2.",solid tumors pembrolizumab titration cohort 1 q3w part a2,during cycle 1 participants received pembrolizumab dose titration from 0 005 mg kg to 0 3 mg kg to 2 0 mg kg on days 1 8 and 22 administered as an iv infusion over 30 minutes participants received 2 mg kg every 3 weeks q3w starting with cycle 2,precise_title,100,100,,"[{""arm_id"": ""NCT01295827_A4"", ""arm_group_title_raw"": ""Solid Tumors: Pembrolizumab Titration Cohort 1 Q3W (Part A2)"", ""arm_group_desc_raw"": ""During Cycle 1 participants received pembrolizumab dose titration from 0.005 mg/kg to 0.3 mg/kg to 2.0 mg/kg on Days 1, 8, and 22, administered as an IV infusion over 30 minutes. Participants received 2 mg/kg every 3 weeks (Q3W) starting with Cycle 2."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT01295827_A5"", ""arm_group_title_raw"": ""Solid Tumors: Pembrolizumab Titration Cohort 2 Q3W (Part A2)"", ""arm_group_desc_raw"": ""During Cycle 1 participants received pembrolizumab dose titration from 0.02 mg/kg to 0.3 mg/kg to 2.0 mg/kg on Days 1, 8, and 22, administered as an IV infusion over 30 minutes. Participants received 2 mg/kg Q3W starting with Cycle 2."", ""title_score"": 98, ""desc_score"": 96}, {""arm_id"": ""NCT01295827_A6"", ""arm_group_title_raw"": ""Solid Tumors: Pembrolizumab Titration Cohort 3 Q3W (Part A2)"", ""arm_group_desc_raw"": ""During Cycle 1 participants received pembrolizumab dose titration from 0.06 mg/kg to 1.0 mg/kg to 10 mg/kg on Days 1, 8, and 22, administered as an IV infusion over 30 minutes. Participants received 10 mg/kg Q3W starting with Cycle 2."", ""title_score"": 98, ""desc_score"": 83}]"
NCT01295827,Pembrolizumab,NCT01295827_A5,Number of Participants Who Experienced an Adverse Event (AE),Primary,,[],,,,,"[{""measure_title"": ""Number of Participants Who Experienced an Adverse Event (AE)"", ""units"": ""Participants"", ""param"": ""Number"", ""values"": [{""group_id"": ""O5"", ""value"": ""3""}]}]",Participants,[],,,[],,,,,,,,,,O5,Solid Tumors: Pembrolizumab Titration Cohort 2 Q3W (Part A2),"During Cycle 1 participants received pembrolizumab dose titration from 0.02 mg/kg to 0.3 mg/kg to 2.0 mg/kg on Days 1, 8, and 22, administered as an IV infusion over 30 minutes. Participants received 2 mg/kg Q3W starting with Cycle 2.",solid tumors pembrolizumab titration cohort 2 q3w part a2,during cycle 1 participants received pembrolizumab dose titration from 0 02 mg kg to 0 3 mg kg to 2 0 mg kg on days 1 8 and 22 administered as an iv infusion over 30 minutes participants received 2 mg kg q3w starting with cycle 2,NCT01295827_A5,Solid Tumors: Pembrolizumab Titration Cohort 2 Q3W (Part A2),"During Cycle 1 participants received pembrolizumab dose titration from 0.02 mg/kg to 0.3 mg/kg to 2.0 mg/kg on Days 1, 8, and 22, administered as an IV infusion over 30 minutes. Participants received 2 mg/kg Q3W starting with Cycle 2.",solid tumors pembrolizumab titration cohort 2 q3w part a2,during cycle 1 participants received pembrolizumab dose titration from 0 02 mg kg to 0 3 mg kg to 2 0 mg kg on days 1 8 and 22 administered as an iv infusion over 30 minutes participants received 2 mg kg q3w starting with cycle 2,precise_title,100,100,,"[{""arm_id"": ""NCT01295827_A5"", ""arm_group_title_raw"": ""Solid Tumors: Pembrolizumab Titration Cohort 2 Q3W (Part A2)"", ""arm_group_desc_raw"": ""During Cycle 1 participants received pembrolizumab dose titration from 0.02 mg/kg to 0.3 mg/kg to 2.0 mg/kg on Days 1, 8, and 22, administered as an IV infusion over 30 minutes. Participants received 2 mg/kg Q3W starting with Cycle 2."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT01295827_A4"", ""arm_group_title_raw"": ""Solid Tumors: Pembrolizumab Titration Cohort 1 Q3W (Part A2)"", ""arm_group_desc_raw"": ""During Cycle 1 participants received pembrolizumab dose titration from 0.005 mg/kg to 0.3 mg/kg to 2.0 mg/kg on Days 1, 8, and 22, administered as an IV infusion over 30 minutes. Participants received 2 mg/kg every 3 weeks (Q3W) starting with Cycle 2."", ""title_score"": 98, ""desc_score"": 96}, {""arm_id"": ""NCT01295827_A6"", ""arm_group_title_raw"": ""Solid Tumors: Pembrolizumab Titration Cohort 3 Q3W (Part A2)"", ""arm_group_desc_raw"": ""During Cycle 1 participants received pembrolizumab dose titration from 0.06 mg/kg to 1.0 mg/kg to 10 mg/kg on Days 1, 8, and 22, administered as an IV infusion over 30 minutes. Participants received 10 mg/kg Q3W starting with Cycle 2."", ""title_score"": 98, ""desc_score"": 88}]"
NCT01295827,Pembrolizumab,NCT01295827_A6,Number of Participants Who Experienced an Adverse Event (AE),Primary,,[],,,,,"[{""measure_title"": ""Number of Participants Who Experienced an Adverse Event (AE)"", ""units"": ""Participants"", ""param"": ""Number"", ""values"": [{""group_id"": ""O6"", ""value"": ""6""}]}]",Participants,[],,,[],,,,,,,,,,O6,Solid Tumors: Pembrolizumab Titration Cohort 3 Q3W (Part A2),"During Cycle 1 participants received pembrolizumab dose titration from 0.06 mg/kg to 1.0 mg/kg to 10 mg/kg on Days 1, 8, and 22, administered as an IV infusion over 30 minutes. Participants received 10 mg/kg Q3W starting with Cycle 2.",solid tumors pembrolizumab titration cohort 3 q3w part a2,during cycle 1 participants received pembrolizumab dose titration from 0 06 mg kg to 1 0 mg kg to 10 mg kg on days 1 8 and 22 administered as an iv infusion over 30 minutes participants received 10 mg kg q3w starting with cycle 2,NCT01295827_A6,Solid Tumors: Pembrolizumab Titration Cohort 3 Q3W (Part A2),"During Cycle 1 participants received pembrolizumab dose titration from 0.06 mg/kg to 1.0 mg/kg to 10 mg/kg on Days 1, 8, and 22, administered as an IV infusion over 30 minutes. Participants received 10 mg/kg Q3W starting with Cycle 2.",solid tumors pembrolizumab titration cohort 3 q3w part a2,during cycle 1 participants received pembrolizumab dose titration from 0 06 mg kg to 1 0 mg kg to 10 mg kg on days 1 8 and 22 administered as an iv infusion over 30 minutes participants received 10 mg kg q3w starting with cycle 2,precise_title,100,100,,"[{""arm_id"": ""NCT01295827_A6"", ""arm_group_title_raw"": ""Solid Tumors: Pembrolizumab Titration Cohort 3 Q3W (Part A2)"", ""arm_group_desc_raw"": ""During Cycle 1 participants received pembrolizumab dose titration from 0.06 mg/kg to 1.0 mg/kg to 10 mg/kg on Days 1, 8, and 22, administered as an IV infusion over 30 minutes. Participants received 10 mg/kg Q3W starting with Cycle 2."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT01295827_A5"", ""arm_group_title_raw"": ""Solid Tumors: Pembrolizumab Titration Cohort 2 Q3W (Part A2)"", ""arm_group_desc_raw"": ""During Cycle 1 participants received pembrolizumab dose titration from 0.02 mg/kg to 0.3 mg/kg to 2.0 mg/kg on Days 1, 8, and 22, administered as an IV infusion over 30 minutes. Participants received 2 mg/kg Q3W starting with Cycle 2."", ""title_score"": 98, ""desc_score"": 82}, {""arm_id"": ""NCT01295827_A4"", ""arm_group_title_raw"": ""Solid Tumors: Pembrolizumab Titration Cohort 1 Q3W (Part A2)"", ""arm_group_desc_raw"": ""During Cycle 1 participants received pembrolizumab dose titration from 0.005 mg/kg to 0.3 mg/kg to 2.0 mg/kg on Days 1, 8, and 22, administered as an IV infusion over 30 minutes. Participants received 2 mg/kg every 3 weeks (Q3W) starting with Cycle 2."", ""title_score"": 98, ""desc_score"": 77}]"
NCT01295827,Pembrolizumab,NCT01295827_A7,Number of Participants Who Experienced an Adverse Event (AE),Primary,,[],,,,,"[{""measure_title"": ""Number of Participants Who Experienced an Adverse Event (AE)"", ""units"": ""Participants"", ""param"": ""Number"", ""values"": [{""group_id"": ""O7"", ""value"": ""161""}]}]",Participants,[],,,[],,,,,,,,,,O7,MEL: Pembrolizumab 2 mg/kg Q3W (Parts B+D),"Participants received pembrolizumab IV at a dose of 2 mg/kg Q2W. After Amendment 3, participants received dosing Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data.",mel pembrolizumab 2 mg kg q3w parts b d,participants received pembrolizumab iv at a dose of 2 mg kg q2w after amendment 3 participants received dosing q3w after amendment 10 all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab iv q3w based on analysis of safety and efficacy data,NCT01295827_A7,MEL: Pembrolizumab 2 mg/kg Q3W (Parts B+D),"Participants received pembrolizumab IV at a dose of 2 mg/kg Q2W. After Amendment 3, participants received dosing Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data.",mel pembrolizumab 2 mg kg q3w parts b d,participants received pembrolizumab iv at a dose of 2 mg kg q2w after amendment 3 participants received dosing q3w after amendment 10 all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab iv q3w based on analysis of safety and efficacy data,precise_title,100,100,,"[{""arm_id"": ""NCT01295827_A7"", ""arm_group_title_raw"": ""MEL: Pembrolizumab 2 mg/kg Q3W (Parts B+D)"", ""arm_group_desc_raw"": ""Participants received pembrolizumab IV at a dose of 2 mg/kg Q2W. After Amendment 3, participants received dosing Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT01295827_A8"", ""arm_group_title_raw"": ""MEL: Pembrolizumab 10 mg/kg Q3W (Parts B+D)"", ""arm_group_desc_raw"": ""Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W. After Amendment 7, participants received dosing Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data."", ""title_score"": 96, ""desc_score"": 99}, {""arm_id"": ""NCT01295827_A10"", ""arm_group_title_raw"": ""NSCLC: Pembrolizumab 2 mg/kg Q3W (Part F)"", ""arm_group_desc_raw"": ""Participants received pembrolizumab IV at a dose of 2 mg/kg Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data."", ""title_score"": 86, ""desc_score"": 90}]"
NCT01295827,Pembrolizumab,NCT01295827_A8,Number of Participants Who Experienced an Adverse Event (AE),Primary,,[],,,,,"[{""measure_title"": ""Number of Participants Who Experienced an Adverse Event (AE)"", ""units"": ""Participants"", ""param"": ""Number"", ""values"": [{""group_id"": ""O8"", ""value"": ""308""}]}]",Participants,[],,,[],,,,,,,,,,O8,MEL: Pembrolizumab 10 mg/kg Q3W (Parts B+D),"Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W. After Amendment 7, participants received dosing Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data.",mel pembrolizumab 10 mg kg q3w parts b d,participants received pembrolizumab iv at a dose of 10 mg kg q2w after amendment 7 participants received dosing q3w after amendment 10 all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab iv q3w based on analysis of safety and efficacy data,NCT01295827_A8,MEL: Pembrolizumab 10 mg/kg Q3W (Parts B+D),"Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W. After Amendment 7, participants received dosing Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data.",mel pembrolizumab 10 mg kg q3w parts b d,participants received pembrolizumab iv at a dose of 10 mg kg q2w after amendment 7 participants received dosing q3w after amendment 10 all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab iv q3w based on analysis of safety and efficacy data,precise_title,100,100,,"[{""arm_id"": ""NCT01295827_A8"", ""arm_group_title_raw"": ""MEL: Pembrolizumab 10 mg/kg Q3W (Parts B+D)"", ""arm_group_desc_raw"": ""Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W. After Amendment 7, participants received dosing Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT01295827_A7"", ""arm_group_title_raw"": ""MEL: Pembrolizumab 2 mg/kg Q3W (Parts B+D)"", ""arm_group_desc_raw"": ""Participants received pembrolizumab IV at a dose of 2 mg/kg Q2W. After Amendment 3, participants received dosing Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data."", ""title_score"": 96, ""desc_score"": 99}, {""arm_id"": ""NCT01295827_A10"", ""arm_group_title_raw"": ""NSCLC: Pembrolizumab 2 mg/kg Q3W (Part F)"", ""arm_group_desc_raw"": ""Participants received pembrolizumab IV at a dose of 2 mg/kg Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data."", ""title_score"": 82, ""desc_score"": 89}]"
NCT01295827,Pembrolizumab,NCT01295827_A9,Number of Participants Who Experienced an Adverse Event (AE),Primary,,[],,,,,"[{""measure_title"": ""Number of Participants Who Experienced an Adverse Event (AE)"", ""units"": ""Participants"", ""param"": ""Number"", ""values"": [{""group_id"": ""O9"", ""value"": ""178""}]}]",Participants,[],,,[],,,,,,,,,,O9,MEL: Pembrolizumab 10 mg/kg Q2W (Part B),"Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data.",mel pembrolizumab 10 mg kg q2w part b,participants received pembrolizumab iv at a dose of 10 mg kg q2w after amendment 10 all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab iv q3w based on analysis of safety and efficacy data,NCT01295827_A9,MEL: Pembrolizumab 10 mg/kg Q2W (Part B),"Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data.",mel pembrolizumab 10 mg kg q2w part b,participants received pembrolizumab iv at a dose of 10 mg kg q2w after amendment 10 all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab iv q3w based on analysis of safety and efficacy data,precise_title,100,100,,"[{""arm_id"": ""NCT01295827_A9"", ""arm_group_title_raw"": ""MEL: Pembrolizumab 10 mg/kg Q2W (Part B)"", ""arm_group_desc_raw"": ""Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT01295827_A12"", ""arm_group_title_raw"": ""NSCLC: Pembrolizumab 10 mg/kg Q2W (Part F)"", ""arm_group_desc_raw"": ""Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data."", ""title_score"": 89, ""desc_score"": 100}, {""arm_id"": ""NCT01295827_A11"", ""arm_group_title_raw"": ""NSCLC: Pembrolizumab 10 mg/kg Q3W (Parts C+F)"", ""arm_group_desc_raw"": ""Participants received pembrolizumab IV at a dose of 10 mg/kg Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data."", ""title_score"": 84, ""desc_score"": 100}]"
NCT01295827,Pembrolizumab,NCT01295827_A10,Number of Participants Who Experienced an Adverse Event (AE),Primary,,[],,,,,"[{""measure_title"": ""Number of Participants Who Experienced an Adverse Event (AE)"", ""units"": ""Participants"", ""param"": ""Number"", ""values"": [{""group_id"": ""O10"", ""value"": ""60""}]}]",Participants,[],,,[],,,,,,,,,,O10,NSCLC: Pembrolizumab 2 mg/kg Q3W (Part F),"Participants received pembrolizumab IV at a dose of 2 mg/kg Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data.",nsclc pembrolizumab 2 mg kg q3w part f,participants received pembrolizumab iv at a dose of 2 mg kg q3w after amendment 10 all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab iv q3w based on analysis of safety and efficacy data,NCT01295827_A10,NSCLC: Pembrolizumab 2 mg/kg Q3W (Part F),"Participants received pembrolizumab IV at a dose of 2 mg/kg Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data.",nsclc pembrolizumab 2 mg kg q3w part f,participants received pembrolizumab iv at a dose of 2 mg kg q3w after amendment 10 all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab iv q3w based on analysis of safety and efficacy data,precise_title,100,100,,"[{""arm_id"": ""NCT01295827_A10"", ""arm_group_title_raw"": ""NSCLC: Pembrolizumab 2 mg/kg Q3W (Part F)"", ""arm_group_desc_raw"": ""Participants received pembrolizumab IV at a dose of 2 mg/kg Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT01295827_A11"", ""arm_group_title_raw"": ""NSCLC: Pembrolizumab 10 mg/kg Q3W (Parts C+F)"", ""arm_group_desc_raw"": ""Participants received pembrolizumab IV at a dose of 10 mg/kg Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data."", ""title_score"": 92, ""desc_score"": 99}, {""arm_id"": ""NCT01295827_A7"", ""arm_group_title_raw"": ""MEL: Pembrolizumab 2 mg/kg Q3W (Parts B+D)"", ""arm_group_desc_raw"": ""Participants received pembrolizumab IV at a dose of 2 mg/kg Q2W. After Amendment 3, participants received dosing Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data."", ""title_score"": 86, ""desc_score"": 90}]"
NCT01295827,Pembrolizumab,NCT01295827_A11,Number of Participants Who Experienced an Adverse Event (AE),Primary,,[],,,,,"[{""measure_title"": ""Number of Participants Who Experienced an Adverse Event (AE)"", ""units"": ""Participants"", ""param"": ""Number"", ""values"": [{""group_id"": ""O11"", ""value"": ""277""}]}]",Participants,[],,,[],,,,,,,,,,O11,NSCLC: Pembrolizumab 10 mg/kg Q3W (Parts C+F),"Participants received pembrolizumab IV at a dose of 10 mg/kg Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data.",nsclc pembrolizumab 10 mg kg q3w parts c f,participants received pembrolizumab iv at a dose of 10 mg kg q3w after amendment 10 all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab iv q3w based on analysis of safety and efficacy data,NCT01295827_A11,NSCLC: Pembrolizumab 10 mg/kg Q3W (Parts C+F),"Participants received pembrolizumab IV at a dose of 10 mg/kg Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data.",nsclc pembrolizumab 10 mg kg q3w parts c f,participants received pembrolizumab iv at a dose of 10 mg kg q3w after amendment 10 all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab iv q3w based on analysis of safety and efficacy data,precise_title,100,100,,"[{""arm_id"": ""NCT01295827_A11"", ""arm_group_title_raw"": ""NSCLC: Pembrolizumab 10 mg/kg Q3W (Parts C+F)"", ""arm_group_desc_raw"": ""Participants received pembrolizumab IV at a dose of 10 mg/kg Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT01295827_A12"", ""arm_group_title_raw"": ""NSCLC: Pembrolizumab 10 mg/kg Q2W (Part F)"", ""arm_group_desc_raw"": ""Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data."", ""title_score"": 94, ""desc_score"": 100}, {""arm_id"": ""NCT01295827_A9"", ""arm_group_title_raw"": ""MEL: Pembrolizumab 10 mg/kg Q2W (Part B)"", ""arm_group_desc_raw"": ""Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data."", ""title_score"": 84, ""desc_score"": 100}]"
NCT01295827,Pembrolizumab,NCT01295827_A12,Number of Participants Who Experienced an Adverse Event (AE),Primary,,[],,,,,"[{""measure_title"": ""Number of Participants Who Experienced an Adverse Event (AE)"", ""units"": ""Participants"", ""param"": ""Number"", ""values"": [{""group_id"": ""O12"", ""value"": ""198""}]}]",Participants,[],,,[],,,,,,,,,,O12,NSCLC: Pembrolizumab 10 mg/kg Q2W (Part F),"Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data.",nsclc pembrolizumab 10 mg kg q2w part f,participants received pembrolizumab iv at a dose of 10 mg kg q2w after amendment 10 all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab iv q3w based on analysis of safety and efficacy data,NCT01295827_A12,NSCLC: Pembrolizumab 10 mg/kg Q2W (Part F),"Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data.",nsclc pembrolizumab 10 mg kg q2w part f,participants received pembrolizumab iv at a dose of 10 mg kg q2w after amendment 10 all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab iv q3w based on analysis of safety and efficacy data,precise_title,100,100,,"[{""arm_id"": ""NCT01295827_A12"", ""arm_group_title_raw"": ""NSCLC: Pembrolizumab 10 mg/kg Q2W (Part F)"", ""arm_group_desc_raw"": ""Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT01295827_A11"", ""arm_group_title_raw"": ""NSCLC: Pembrolizumab 10 mg/kg Q3W (Parts C+F)"", ""arm_group_desc_raw"": ""Participants received pembrolizumab IV at a dose of 10 mg/kg Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data."", ""title_score"": 94, ""desc_score"": 100}, {""arm_id"": ""NCT01295827_A9"", ""arm_group_title_raw"": ""MEL: Pembrolizumab 10 mg/kg Q2W (Part B)"", ""arm_group_desc_raw"": ""Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data."", ""title_score"": 89, ""desc_score"": 100}]"
NCT01295827,Pembrolizumab,NCT01295827_A1,Overall Response Rate (ORR) According to Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Integrated Radiology and Oncology (IRO): Melanoma Participants (Parts B Plus D),Primary,,[],,,,,[],,[],,,[],,,,,,,,,,O1,Solid Tumors: Pembrolizumab 1 mg/kg Q2W (Part A),During Cycle 1 participants received a dose of 1 mg/kg pembrolizumab IV infusion over 30 minutes on Day 1 of a 28-day cycle for evaluation of dose-limiting toxicities and pharmacokinetics. Participants received pembrolizumab IV at a dose of 1 mg/kg Q2W starting with Cycle 2.,solid tumors pembrolizumab 1 mg kg q2w part a,during cycle 1 participants received a dose of 1 mg kg pembrolizumab iv infusion over 30 minutes on day 1 of a 28 day cycle for evaluation of dose limiting toxicities and pharmacokinetics participants received pembrolizumab iv at a dose of 1 mg kg q2w starting with cycle 2,NCT01295827_A1,Solid Tumors: Pembrolizumab 1 mg/kg Q2W (Part A),During Cycle 1 participants received a dose of 1 mg/kg pembrolizumab intravenous (IV) infusion over 30 minutes on Day 1 of a 28-day cycle for evaluation of dose-limiting toxicities and pharmacokinetics. Participants received pembrolizumab IV at a dose of 1 mg/kg every 2 weeks (Q2W) starting with Cycle 2.,solid tumors pembrolizumab 1 mg kg q2w part a,during cycle 1 participants received a dose of 1 mg kg pembrolizumab intravenous iv infusion over 30 minutes on day 1 of a 28 day cycle for evaluation of dose limiting toxicities and pharmacokinetics participants received pembrolizumab iv at a dose of 1 mg kg every 2 weeks q2w starting with cycle 2,precise_title,100,95,,"[{""arm_id"": ""NCT01295827_A3"", ""arm_group_title_raw"": ""Solid Tumors: Pembrolizumab 10 mg/kg Q2W (Parts A+A1)"", ""arm_group_desc_raw"": ""During Cycle 1 participants received a dose of 10 mg/kg pembrolizumab IV infusion over 30 minutes on Day 1 of a 28-day cycle for evaluation of dose-limiting toxicities and pharmacokinetics. Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W starting with Cycle 2."", ""title_score"": 95, ""desc_score"": 100}, {""arm_id"": ""NCT01295827_A2"", ""arm_group_title_raw"": ""Solid Tumors: Pembrolizumab 3 mg/kg Q2W (Part A)"", ""arm_group_desc_raw"": ""During Cycle 1 participants received a dose of 3 mg/kg pembrolizumab IV infusion over 30 minutes on Day 1 of a 28-day cycle for evaluation of dose-limiting toxicities and pharmacokinetics. Participants received pembrolizumab IV at a dose of 3 mg/kg Q2W starting with Cycle 2."", ""title_score"": 98, ""desc_score"": 99}, {""arm_id"": ""NCT01295827_A1"", ""arm_group_title_raw"": ""Solid Tumors: Pembrolizumab 1 mg/kg Q2W (Part A)"", ""arm_group_desc_raw"": ""During Cycle 1 participants received a dose of 1 mg/kg pembrolizumab intravenous (IV) infusion over 30 minutes on Day 1 of a 28-day cycle for evaluation of dose-limiting toxicities and pharmacokinetics. Participants received pembrolizumab IV at a dose of 1 mg/kg every 2 weeks (Q2W) starting with Cycle 2."", ""title_score"": 100, ""desc_score"": 95}]"
NCT01295827,Pembrolizumab,NCT01295827_A2,Overall Response Rate (ORR) According to Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Integrated Radiology and Oncology (IRO): Melanoma Participants (Parts B Plus D),Primary,,[],,,,,[],,[],,,[],,,,,,,,,,O2,Solid Tumors: Pembrolizumab 3 mg/kg Q2W (Part A),During Cycle 1 participants received a dose of 3 mg/kg pembrolizumab IV infusion over 30 minutes on Day 1 of a 28-day cycle for evaluation of dose-limiting toxicities and pharmacokinetics. Participants received pembrolizumab IV at a dose of 3 mg/kg Q2W starting with Cycle 2.,solid tumors pembrolizumab 3 mg kg q2w part a,during cycle 1 participants received a dose of 3 mg kg pembrolizumab iv infusion over 30 minutes on day 1 of a 28 day cycle for evaluation of dose limiting toxicities and pharmacokinetics participants received pembrolizumab iv at a dose of 3 mg kg q2w starting with cycle 2,NCT01295827_A2,Solid Tumors: Pembrolizumab 3 mg/kg Q2W (Part A),During Cycle 1 participants received a dose of 3 mg/kg pembrolizumab IV infusion over 30 minutes on Day 1 of a 28-day cycle for evaluation of dose-limiting toxicities and pharmacokinetics. Participants received pembrolizumab IV at a dose of 3 mg/kg Q2W starting with Cycle 2.,solid tumors pembrolizumab 3 mg kg q2w part a,during cycle 1 participants received a dose of 3 mg kg pembrolizumab iv infusion over 30 minutes on day 1 of a 28 day cycle for evaluation of dose limiting toxicities and pharmacokinetics participants received pembrolizumab iv at a dose of 3 mg kg q2w starting with cycle 2,precise_title,100,100,,"[{""arm_id"": ""NCT01295827_A2"", ""arm_group_title_raw"": ""Solid Tumors: Pembrolizumab 3 mg/kg Q2W (Part A)"", ""arm_group_desc_raw"": ""During Cycle 1 participants received a dose of 3 mg/kg pembrolizumab IV infusion over 30 minutes on Day 1 of a 28-day cycle for evaluation of dose-limiting toxicities and pharmacokinetics. Participants received pembrolizumab IV at a dose of 3 mg/kg Q2W starting with Cycle 2."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT01295827_A3"", ""arm_group_title_raw"": ""Solid Tumors: Pembrolizumab 10 mg/kg Q2W (Parts A+A1)"", ""arm_group_desc_raw"": ""During Cycle 1 participants received a dose of 10 mg/kg pembrolizumab IV infusion over 30 minutes on Day 1 of a 28-day cycle for evaluation of dose-limiting toxicities and pharmacokinetics. Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W starting with Cycle 2."", ""title_score"": 93, ""desc_score"": 99}, {""arm_id"": ""NCT01295827_A1"", ""arm_group_title_raw"": ""Solid Tumors: Pembrolizumab 1 mg/kg Q2W (Part A)"", ""arm_group_desc_raw"": ""During Cycle 1 participants received a dose of 1 mg/kg pembrolizumab intravenous (IV) infusion over 30 minutes on Day 1 of a 28-day cycle for evaluation of dose-limiting toxicities and pharmacokinetics. Participants received pembrolizumab IV at a dose of 1 mg/kg every 2 weeks (Q2W) starting with Cycle 2."", ""title_score"": 98, ""desc_score"": 93}]"
NCT01295827,Pembrolizumab,NCT01295827_A3,Overall Response Rate (ORR) According to Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Integrated Radiology and Oncology (IRO): Melanoma Participants (Parts B Plus D),Primary,,[],,,,,[],,[],,,[],,,,,,,,,,O3,Solid Tumors: Pembrolizumab 10 mg/kg Q2W (Parts A+A1),During Cycle 1 participants received a dose of 10 mg/kg pembrolizumab IV infusion over 30 minutes on Day 1 of a 28-day cycle for evaluation of dose-limiting toxicities and pharmacokinetics. Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W starting with Cycle 2.,solid tumors pembrolizumab 10 mg kg q2w parts a a1,during cycle 1 participants received a dose of 10 mg kg pembrolizumab iv infusion over 30 minutes on day 1 of a 28 day cycle for evaluation of dose limiting toxicities and pharmacokinetics participants received pembrolizumab iv at a dose of 10 mg kg q2w starting with cycle 2,NCT01295827_A3,Solid Tumors: Pembrolizumab 10 mg/kg Q2W (Parts A+A1),During Cycle 1 participants received a dose of 10 mg/kg pembrolizumab IV infusion over 30 minutes on Day 1 of a 28-day cycle for evaluation of dose-limiting toxicities and pharmacokinetics. Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W starting with Cycle 2.,solid tumors pembrolizumab 10 mg kg q2w parts a a1,during cycle 1 participants received a dose of 10 mg kg pembrolizumab iv infusion over 30 minutes on day 1 of a 28 day cycle for evaluation of dose limiting toxicities and pharmacokinetics participants received pembrolizumab iv at a dose of 10 mg kg q2w starting with cycle 2,precise_title,100,100,,"[{""arm_id"": ""NCT01295827_A3"", ""arm_group_title_raw"": ""Solid Tumors: Pembrolizumab 10 mg/kg Q2W (Parts A+A1)"", ""arm_group_desc_raw"": ""During Cycle 1 participants received a dose of 10 mg/kg pembrolizumab IV infusion over 30 minutes on Day 1 of a 28-day cycle for evaluation of dose-limiting toxicities and pharmacokinetics. Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W starting with Cycle 2."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT01295827_A2"", ""arm_group_title_raw"": ""Solid Tumors: Pembrolizumab 3 mg/kg Q2W (Part A)"", ""arm_group_desc_raw"": ""During Cycle 1 participants received a dose of 3 mg/kg pembrolizumab IV infusion over 30 minutes on Day 1 of a 28-day cycle for evaluation of dose-limiting toxicities and pharmacokinetics. Participants received pembrolizumab IV at a dose of 3 mg/kg Q2W starting with Cycle 2."", ""title_score"": 93, ""desc_score"": 99}, {""arm_id"": ""NCT01295827_A1"", ""arm_group_title_raw"": ""Solid Tumors: Pembrolizumab 1 mg/kg Q2W (Part A)"", ""arm_group_desc_raw"": ""During Cycle 1 participants received a dose of 1 mg/kg pembrolizumab intravenous (IV) infusion over 30 minutes on Day 1 of a 28-day cycle for evaluation of dose-limiting toxicities and pharmacokinetics. Participants received pembrolizumab IV at a dose of 1 mg/kg every 2 weeks (Q2W) starting with Cycle 2."", ""title_score"": 95, ""desc_score"": 93}]"
NCT01295827,Pembrolizumab,NCT01295827_A4,Overall Response Rate (ORR) According to Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Integrated Radiology and Oncology (IRO): Melanoma Participants (Parts B Plus D),Primary,,[],,,,,[],,[],,,[],,,,,,,,,,O4,Solid Tumors: Pembrolizumab Titration Cohort 1 Q3W (Part A2),"During Cycle 1 participants received pembrolizumab dose titration from 0.005 mg/kg to 0.3 mg/kg to 2.0 mg/kg on Days 1, 8, and 22, administered as an IV infusion over 30 minutes. Participants received 2 mg/kg every 3 weeks (Q3W) starting with Cycle 2.",solid tumors pembrolizumab titration cohort 1 q3w part a2,during cycle 1 participants received pembrolizumab dose titration from 0 005 mg kg to 0 3 mg kg to 2 0 mg kg on days 1 8 and 22 administered as an iv infusion over 30 minutes participants received 2 mg kg every 3 weeks q3w starting with cycle 2,NCT01295827_A4,Solid Tumors: Pembrolizumab Titration Cohort 1 Q3W (Part A2),"During Cycle 1 participants received pembrolizumab dose titration from 0.005 mg/kg to 0.3 mg/kg to 2.0 mg/kg on Days 1, 8, and 22, administered as an IV infusion over 30 minutes. Participants received 2 mg/kg every 3 weeks (Q3W) starting with Cycle 2.",solid tumors pembrolizumab titration cohort 1 q3w part a2,during cycle 1 participants received pembrolizumab dose titration from 0 005 mg kg to 0 3 mg kg to 2 0 mg kg on days 1 8 and 22 administered as an iv infusion over 30 minutes participants received 2 mg kg every 3 weeks q3w starting with cycle 2,precise_title,100,100,,"[{""arm_id"": ""NCT01295827_A4"", ""arm_group_title_raw"": ""Solid Tumors: Pembrolizumab Titration Cohort 1 Q3W (Part A2)"", ""arm_group_desc_raw"": ""During Cycle 1 participants received pembrolizumab dose titration from 0.005 mg/kg to 0.3 mg/kg to 2.0 mg/kg on Days 1, 8, and 22, administered as an IV infusion over 30 minutes. Participants received 2 mg/kg every 3 weeks (Q3W) starting with Cycle 2."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT01295827_A5"", ""arm_group_title_raw"": ""Solid Tumors: Pembrolizumab Titration Cohort 2 Q3W (Part A2)"", ""arm_group_desc_raw"": ""During Cycle 1 participants received pembrolizumab dose titration from 0.02 mg/kg to 0.3 mg/kg to 2.0 mg/kg on Days 1, 8, and 22, administered as an IV infusion over 30 minutes. Participants received 2 mg/kg Q3W starting with Cycle 2."", ""title_score"": 98, ""desc_score"": 96}, {""arm_id"": ""NCT01295827_A6"", ""arm_group_title_raw"": ""Solid Tumors: Pembrolizumab Titration Cohort 3 Q3W (Part A2)"", ""arm_group_desc_raw"": ""During Cycle 1 participants received pembrolizumab dose titration from 0.06 mg/kg to 1.0 mg/kg to 10 mg/kg on Days 1, 8, and 22, administered as an IV infusion over 30 minutes. Participants received 10 mg/kg Q3W starting with Cycle 2."", ""title_score"": 98, ""desc_score"": 83}]"
NCT01295827,Pembrolizumab,NCT01295827_A5,Overall Response Rate (ORR) According to Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Integrated Radiology and Oncology (IRO): Melanoma Participants (Parts B Plus D),Primary,,[],,,,,[],,[],,,[],,,,,,,,,,O5,Solid Tumors: Pembrolizumab Titration Cohort 2 Q3W (Part A2),"During Cycle 1 participants received pembrolizumab dose titration from 0.02 mg/kg to 0.3 mg/kg to 2.0 mg/kg on Days 1, 8, and 22, administered as an IV infusion over 30 minutes. Participants received 2 mg/kg Q3W starting with Cycle 2.",solid tumors pembrolizumab titration cohort 2 q3w part a2,during cycle 1 participants received pembrolizumab dose titration from 0 02 mg kg to 0 3 mg kg to 2 0 mg kg on days 1 8 and 22 administered as an iv infusion over 30 minutes participants received 2 mg kg q3w starting with cycle 2,NCT01295827_A5,Solid Tumors: Pembrolizumab Titration Cohort 2 Q3W (Part A2),"During Cycle 1 participants received pembrolizumab dose titration from 0.02 mg/kg to 0.3 mg/kg to 2.0 mg/kg on Days 1, 8, and 22, administered as an IV infusion over 30 minutes. Participants received 2 mg/kg Q3W starting with Cycle 2.",solid tumors pembrolizumab titration cohort 2 q3w part a2,during cycle 1 participants received pembrolizumab dose titration from 0 02 mg kg to 0 3 mg kg to 2 0 mg kg on days 1 8 and 22 administered as an iv infusion over 30 minutes participants received 2 mg kg q3w starting with cycle 2,precise_title,100,100,,"[{""arm_id"": ""NCT01295827_A5"", ""arm_group_title_raw"": ""Solid Tumors: Pembrolizumab Titration Cohort 2 Q3W (Part A2)"", ""arm_group_desc_raw"": ""During Cycle 1 participants received pembrolizumab dose titration from 0.02 mg/kg to 0.3 mg/kg to 2.0 mg/kg on Days 1, 8, and 22, administered as an IV infusion over 30 minutes. Participants received 2 mg/kg Q3W starting with Cycle 2."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT01295827_A4"", ""arm_group_title_raw"": ""Solid Tumors: Pembrolizumab Titration Cohort 1 Q3W (Part A2)"", ""arm_group_desc_raw"": ""During Cycle 1 participants received pembrolizumab dose titration from 0.005 mg/kg to 0.3 mg/kg to 2.0 mg/kg on Days 1, 8, and 22, administered as an IV infusion over 30 minutes. Participants received 2 mg/kg every 3 weeks (Q3W) starting with Cycle 2."", ""title_score"": 98, ""desc_score"": 96}, {""arm_id"": ""NCT01295827_A6"", ""arm_group_title_raw"": ""Solid Tumors: Pembrolizumab Titration Cohort 3 Q3W (Part A2)"", ""arm_group_desc_raw"": ""During Cycle 1 participants received pembrolizumab dose titration from 0.06 mg/kg to 1.0 mg/kg to 10 mg/kg on Days 1, 8, and 22, administered as an IV infusion over 30 minutes. Participants received 10 mg/kg Q3W starting with Cycle 2."", ""title_score"": 98, ""desc_score"": 88}]"
NCT01295827,Pembrolizumab,NCT01295827_A6,Overall Response Rate (ORR) According to Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Integrated Radiology and Oncology (IRO): Melanoma Participants (Parts B Plus D),Primary,,[],,,,,[],,[],,,[],,,,,,,,,,O6,Solid Tumors: Pembrolizumab Titration Cohort 3 Q3W (Part A2),"During Cycle 1 participants received pembrolizumab dose titration from 0.06 mg/kg to 1.0 mg/kg to 10 mg/kg on Days 1, 8, and 22, administered as an IV infusion over 30 minutes. Participants received 10 mg/kg Q3W starting with Cycle 2.",solid tumors pembrolizumab titration cohort 3 q3w part a2,during cycle 1 participants received pembrolizumab dose titration from 0 06 mg kg to 1 0 mg kg to 10 mg kg on days 1 8 and 22 administered as an iv infusion over 30 minutes participants received 10 mg kg q3w starting with cycle 2,NCT01295827_A6,Solid Tumors: Pembrolizumab Titration Cohort 3 Q3W (Part A2),"During Cycle 1 participants received pembrolizumab dose titration from 0.06 mg/kg to 1.0 mg/kg to 10 mg/kg on Days 1, 8, and 22, administered as an IV infusion over 30 minutes. Participants received 10 mg/kg Q3W starting with Cycle 2.",solid tumors pembrolizumab titration cohort 3 q3w part a2,during cycle 1 participants received pembrolizumab dose titration from 0 06 mg kg to 1 0 mg kg to 10 mg kg on days 1 8 and 22 administered as an iv infusion over 30 minutes participants received 10 mg kg q3w starting with cycle 2,precise_title,100,100,,"[{""arm_id"": ""NCT01295827_A6"", ""arm_group_title_raw"": ""Solid Tumors: Pembrolizumab Titration Cohort 3 Q3W (Part A2)"", ""arm_group_desc_raw"": ""During Cycle 1 participants received pembrolizumab dose titration from 0.06 mg/kg to 1.0 mg/kg to 10 mg/kg on Days 1, 8, and 22, administered as an IV infusion over 30 minutes. Participants received 10 mg/kg Q3W starting with Cycle 2."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT01295827_A5"", ""arm_group_title_raw"": ""Solid Tumors: Pembrolizumab Titration Cohort 2 Q3W (Part A2)"", ""arm_group_desc_raw"": ""During Cycle 1 participants received pembrolizumab dose titration from 0.02 mg/kg to 0.3 mg/kg to 2.0 mg/kg on Days 1, 8, and 22, administered as an IV infusion over 30 minutes. Participants received 2 mg/kg Q3W starting with Cycle 2."", ""title_score"": 98, ""desc_score"": 82}, {""arm_id"": ""NCT01295827_A4"", ""arm_group_title_raw"": ""Solid Tumors: Pembrolizumab Titration Cohort 1 Q3W (Part A2)"", ""arm_group_desc_raw"": ""During Cycle 1 participants received pembrolizumab dose titration from 0.005 mg/kg to 0.3 mg/kg to 2.0 mg/kg on Days 1, 8, and 22, administered as an IV infusion over 30 minutes. Participants received 2 mg/kg every 3 weeks (Q3W) starting with Cycle 2."", ""title_score"": 98, ""desc_score"": 77}]"
NCT01295827,Pembrolizumab,NCT01295827_A7,Overall Response Rate (ORR) According to Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Integrated Radiology and Oncology (IRO): Melanoma Participants (Parts B Plus D),Primary,,[],,,,,"[{""measure_title"": ""Overall Response Rate (ORR) According to Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Integrated Radiology and Oncology (IRO): Melanoma Participants (Parts B Plus D)"", ""units"": ""Percentage of Participants"", ""param"": ""Number"", ""dispersion"": ""95% Confidence Interval"", ""values"": [{""group_id"": ""O7"", ""value"": ""30.2"", ""lower"": ""23.3"", ""upper"": ""37.9""}]}]",Percentage of Participants,[],,,[],,,,,,,,,,O7,MEL: Pembrolizumab 2 mg/kg Q3W (Parts B+D),"Participants received pembrolizumab IV at a dose of 2 mg/kg Q2W. After Amendment 3, participants received dosing Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data.",mel pembrolizumab 2 mg kg q3w parts b d,participants received pembrolizumab iv at a dose of 2 mg kg q2w after amendment 3 participants received dosing q3w after amendment 10 all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab iv q3w based on analysis of safety and efficacy data,NCT01295827_A7,MEL: Pembrolizumab 2 mg/kg Q3W (Parts B+D),"Participants received pembrolizumab IV at a dose of 2 mg/kg Q2W. After Amendment 3, participants received dosing Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data.",mel pembrolizumab 2 mg kg q3w parts b d,participants received pembrolizumab iv at a dose of 2 mg kg q2w after amendment 3 participants received dosing q3w after amendment 10 all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab iv q3w based on analysis of safety and efficacy data,precise_title,100,100,,"[{""arm_id"": ""NCT01295827_A7"", ""arm_group_title_raw"": ""MEL: Pembrolizumab 2 mg/kg Q3W (Parts B+D)"", ""arm_group_desc_raw"": ""Participants received pembrolizumab IV at a dose of 2 mg/kg Q2W. After Amendment 3, participants received dosing Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT01295827_A8"", ""arm_group_title_raw"": ""MEL: Pembrolizumab 10 mg/kg Q3W (Parts B+D)"", ""arm_group_desc_raw"": ""Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W. After Amendment 7, participants received dosing Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data."", ""title_score"": 96, ""desc_score"": 99}, {""arm_id"": ""NCT01295827_A10"", ""arm_group_title_raw"": ""NSCLC: Pembrolizumab 2 mg/kg Q3W (Part F)"", ""arm_group_desc_raw"": ""Participants received pembrolizumab IV at a dose of 2 mg/kg Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data."", ""title_score"": 86, ""desc_score"": 90}]"
NCT01295827,Pembrolizumab,NCT01295827_A8,Overall Response Rate (ORR) According to Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Integrated Radiology and Oncology (IRO): Melanoma Participants (Parts B Plus D),Primary,,[],,,,,"[{""measure_title"": ""Overall Response Rate (ORR) According to Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Integrated Radiology and Oncology (IRO): Melanoma Participants (Parts B Plus D)"", ""units"": ""Percentage of Participants"", ""param"": ""Number"", ""dispersion"": ""95% Confidence Interval"", ""values"": [{""group_id"": ""O8"", ""value"": ""29.4"", ""lower"": ""24.4"", ""upper"": ""34.8""}]}]",Percentage of Participants,[],,,[],,,,,,,,,,O8,MEL: Pembrolizumab 10 mg/kg Q3W (Parts B+D),"Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W. After Amendment 7, participants received dosing Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data.",mel pembrolizumab 10 mg kg q3w parts b d,participants received pembrolizumab iv at a dose of 10 mg kg q2w after amendment 7 participants received dosing q3w after amendment 10 all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab iv q3w based on analysis of safety and efficacy data,NCT01295827_A8,MEL: Pembrolizumab 10 mg/kg Q3W (Parts B+D),"Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W. After Amendment 7, participants received dosing Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data.",mel pembrolizumab 10 mg kg q3w parts b d,participants received pembrolizumab iv at a dose of 10 mg kg q2w after amendment 7 participants received dosing q3w after amendment 10 all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab iv q3w based on analysis of safety and efficacy data,precise_title,100,100,,"[{""arm_id"": ""NCT01295827_A8"", ""arm_group_title_raw"": ""MEL: Pembrolizumab 10 mg/kg Q3W (Parts B+D)"", ""arm_group_desc_raw"": ""Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W. After Amendment 7, participants received dosing Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT01295827_A7"", ""arm_group_title_raw"": ""MEL: Pembrolizumab 2 mg/kg Q3W (Parts B+D)"", ""arm_group_desc_raw"": ""Participants received pembrolizumab IV at a dose of 2 mg/kg Q2W. After Amendment 3, participants received dosing Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data."", ""title_score"": 96, ""desc_score"": 99}, {""arm_id"": ""NCT01295827_A10"", ""arm_group_title_raw"": ""NSCLC: Pembrolizumab 2 mg/kg Q3W (Part F)"", ""arm_group_desc_raw"": ""Participants received pembrolizumab IV at a dose of 2 mg/kg Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data."", ""title_score"": 82, ""desc_score"": 89}]"
NCT01295827,Pembrolizumab,NCT01295827_A9,Overall Response Rate (ORR) According to Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Integrated Radiology and Oncology (IRO): Melanoma Participants (Parts B Plus D),Primary,,[],,,,,"[{""measure_title"": ""Overall Response Rate (ORR) According to Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Integrated Radiology and Oncology (IRO): Melanoma Participants (Parts B Plus D)"", ""units"": ""Percentage of Participants"", ""param"": ""Number"", ""dispersion"": ""95% Confidence Interval"", ""values"": [{""group_id"": ""O9"", ""value"": ""36.7"", ""lower"": ""29.6"", ""upper"": ""44.2""}]}]",Percentage of Participants,[],,,[],,,,,,,,,,O9,MEL: Pembrolizumab 10 mg/kg Q2W (Part B),"Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data.",mel pembrolizumab 10 mg kg q2w part b,participants received pembrolizumab iv at a dose of 10 mg kg q2w after amendment 10 all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab iv q3w based on analysis of safety and efficacy data,NCT01295827_A9,MEL: Pembrolizumab 10 mg/kg Q2W (Part B),"Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data.",mel pembrolizumab 10 mg kg q2w part b,participants received pembrolizumab iv at a dose of 10 mg kg q2w after amendment 10 all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab iv q3w based on analysis of safety and efficacy data,precise_title,100,100,,"[{""arm_id"": ""NCT01295827_A9"", ""arm_group_title_raw"": ""MEL: Pembrolizumab 10 mg/kg Q2W (Part B)"", ""arm_group_desc_raw"": ""Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT01295827_A12"", ""arm_group_title_raw"": ""NSCLC: Pembrolizumab 10 mg/kg Q2W (Part F)"", ""arm_group_desc_raw"": ""Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data."", ""title_score"": 89, ""desc_score"": 100}, {""arm_id"": ""NCT01295827_A11"", ""arm_group_title_raw"": ""NSCLC: Pembrolizumab 10 mg/kg Q3W (Parts C+F)"", ""arm_group_desc_raw"": ""Participants received pembrolizumab IV at a dose of 10 mg/kg Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data."", ""title_score"": 84, ""desc_score"": 100}]"
NCT01295827,Pembrolizumab,NCT01295827_A10,Overall Response Rate (ORR) According to Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Integrated Radiology and Oncology (IRO): Melanoma Participants (Parts B Plus D),Primary,,[],,,,,[],,[],,,[],,,,,,,,,,O10,NSCLC: Pembrolizumab 2 mg/kg Q3W (Part F),"Participants received pembrolizumab IV at a dose of 2 mg/kg Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data.",nsclc pembrolizumab 2 mg kg q3w part f,participants received pembrolizumab iv at a dose of 2 mg kg q3w after amendment 10 all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab iv q3w based on analysis of safety and efficacy data,NCT01295827_A10,NSCLC: Pembrolizumab 2 mg/kg Q3W (Part F),"Participants received pembrolizumab IV at a dose of 2 mg/kg Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data.",nsclc pembrolizumab 2 mg kg q3w part f,participants received pembrolizumab iv at a dose of 2 mg kg q3w after amendment 10 all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab iv q3w based on analysis of safety and efficacy data,precise_title,100,100,,"[{""arm_id"": ""NCT01295827_A10"", ""arm_group_title_raw"": ""NSCLC: Pembrolizumab 2 mg/kg Q3W (Part F)"", ""arm_group_desc_raw"": ""Participants received pembrolizumab IV at a dose of 2 mg/kg Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT01295827_A11"", ""arm_group_title_raw"": ""NSCLC: Pembrolizumab 10 mg/kg Q3W (Parts C+F)"", ""arm_group_desc_raw"": ""Participants received pembrolizumab IV at a dose of 10 mg/kg Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data."", ""title_score"": 92, ""desc_score"": 99}, {""arm_id"": ""NCT01295827_A7"", ""arm_group_title_raw"": ""MEL: Pembrolizumab 2 mg/kg Q3W (Parts B+D)"", ""arm_group_desc_raw"": ""Participants received pembrolizumab IV at a dose of 2 mg/kg Q2W. After Amendment 3, participants received dosing Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data."", ""title_score"": 86, ""desc_score"": 90}]"
NCT01295827,Pembrolizumab,NCT01295827_A11,Overall Response Rate (ORR) According to Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Integrated Radiology and Oncology (IRO): Melanoma Participants (Parts B Plus D),Primary,,[],,,,,[],,[],,,[],,,,,,,,,,O11,NSCLC: Pembrolizumab 10 mg/kg Q3W (Parts C+F),"Participants received pembrolizumab IV at a dose of 10 mg/kg Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data.",nsclc pembrolizumab 10 mg kg q3w parts c f,participants received pembrolizumab iv at a dose of 10 mg kg q3w after amendment 10 all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab iv q3w based on analysis of safety and efficacy data,NCT01295827_A11,NSCLC: Pembrolizumab 10 mg/kg Q3W (Parts C+F),"Participants received pembrolizumab IV at a dose of 10 mg/kg Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data.",nsclc pembrolizumab 10 mg kg q3w parts c f,participants received pembrolizumab iv at a dose of 10 mg kg q3w after amendment 10 all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab iv q3w based on analysis of safety and efficacy data,precise_title,100,100,,"[{""arm_id"": ""NCT01295827_A11"", ""arm_group_title_raw"": ""NSCLC: Pembrolizumab 10 mg/kg Q3W (Parts C+F)"", ""arm_group_desc_raw"": ""Participants received pembrolizumab IV at a dose of 10 mg/kg Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT01295827_A12"", ""arm_group_title_raw"": ""NSCLC: Pembrolizumab 10 mg/kg Q2W (Part F)"", ""arm_group_desc_raw"": ""Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data."", ""title_score"": 94, ""desc_score"": 100}, {""arm_id"": ""NCT01295827_A9"", ""arm_group_title_raw"": ""MEL: Pembrolizumab 10 mg/kg Q2W (Part B)"", ""arm_group_desc_raw"": ""Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data."", ""title_score"": 84, ""desc_score"": 100}]"
NCT01295827,Pembrolizumab,NCT01295827_A12,Overall Response Rate (ORR) According to Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Integrated Radiology and Oncology (IRO): Melanoma Participants (Parts B Plus D),Primary,,[],,,,,[],,[],,,[],,,,,,,,,,O12,NSCLC: Pembrolizumab 10 mg/kg Q2W (Part F),"Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data.",nsclc pembrolizumab 10 mg kg q2w part f,participants received pembrolizumab iv at a dose of 10 mg kg q2w after amendment 10 all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab iv q3w based on analysis of safety and efficacy data,NCT01295827_A12,NSCLC: Pembrolizumab 10 mg/kg Q2W (Part F),"Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data.",nsclc pembrolizumab 10 mg kg q2w part f,participants received pembrolizumab iv at a dose of 10 mg kg q2w after amendment 10 all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab iv q3w based on analysis of safety and efficacy data,precise_title,100,100,,"[{""arm_id"": ""NCT01295827_A12"", ""arm_group_title_raw"": ""NSCLC: Pembrolizumab 10 mg/kg Q2W (Part F)"", ""arm_group_desc_raw"": ""Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT01295827_A11"", ""arm_group_title_raw"": ""NSCLC: Pembrolizumab 10 mg/kg Q3W (Parts C+F)"", ""arm_group_desc_raw"": ""Participants received pembrolizumab IV at a dose of 10 mg/kg Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data."", ""title_score"": 94, ""desc_score"": 100}, {""arm_id"": ""NCT01295827_A9"", ""arm_group_title_raw"": ""MEL: Pembrolizumab 10 mg/kg Q2W (Part B)"", ""arm_group_desc_raw"": ""Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data."", ""title_score"": 89, ""desc_score"": 100}]"
NCT01295827,Pembrolizumab,NCT01295827_A1,ORR According to RECIST 1.1 as Assessed by Independent Review Committee (IRC): Non-Small Cell Lung Cancer (NSCLC) Participants (Parts C Plus F),Primary,,[],,,,,[],,[],,,[],,,,,,,,,,O1,Solid Tumors: Pembrolizumab 1 mg/kg Q2W (Part A),During Cycle 1 participants received a dose of 1 mg/kg pembrolizumab IV infusion over 30 minutes on Day 1 of a 28-day cycle for evaluation of dose-limiting toxicities and pharmacokinetics. Participants received pembrolizumab IV at a dose of 1 mg/kg Q2W starting with Cycle 2.,solid tumors pembrolizumab 1 mg kg q2w part a,during cycle 1 participants received a dose of 1 mg kg pembrolizumab iv infusion over 30 minutes on day 1 of a 28 day cycle for evaluation of dose limiting toxicities and pharmacokinetics participants received pembrolizumab iv at a dose of 1 mg kg q2w starting with cycle 2,NCT01295827_A1,Solid Tumors: Pembrolizumab 1 mg/kg Q2W (Part A),During Cycle 1 participants received a dose of 1 mg/kg pembrolizumab intravenous (IV) infusion over 30 minutes on Day 1 of a 28-day cycle for evaluation of dose-limiting toxicities and pharmacokinetics. Participants received pembrolizumab IV at a dose of 1 mg/kg every 2 weeks (Q2W) starting with Cycle 2.,solid tumors pembrolizumab 1 mg kg q2w part a,during cycle 1 participants received a dose of 1 mg kg pembrolizumab intravenous iv infusion over 30 minutes on day 1 of a 28 day cycle for evaluation of dose limiting toxicities and pharmacokinetics participants received pembrolizumab iv at a dose of 1 mg kg every 2 weeks q2w starting with cycle 2,precise_title,100,95,,"[{""arm_id"": ""NCT01295827_A3"", ""arm_group_title_raw"": ""Solid Tumors: Pembrolizumab 10 mg/kg Q2W (Parts A+A1)"", ""arm_group_desc_raw"": ""During Cycle 1 participants received a dose of 10 mg/kg pembrolizumab IV infusion over 30 minutes on Day 1 of a 28-day cycle for evaluation of dose-limiting toxicities and pharmacokinetics. Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W starting with Cycle 2."", ""title_score"": 95, ""desc_score"": 100}, {""arm_id"": ""NCT01295827_A2"", ""arm_group_title_raw"": ""Solid Tumors: Pembrolizumab 3 mg/kg Q2W (Part A)"", ""arm_group_desc_raw"": ""During Cycle 1 participants received a dose of 3 mg/kg pembrolizumab IV infusion over 30 minutes on Day 1 of a 28-day cycle for evaluation of dose-limiting toxicities and pharmacokinetics. Participants received pembrolizumab IV at a dose of 3 mg/kg Q2W starting with Cycle 2."", ""title_score"": 98, ""desc_score"": 99}, {""arm_id"": ""NCT01295827_A1"", ""arm_group_title_raw"": ""Solid Tumors: Pembrolizumab 1 mg/kg Q2W (Part A)"", ""arm_group_desc_raw"": ""During Cycle 1 participants received a dose of 1 mg/kg pembrolizumab intravenous (IV) infusion over 30 minutes on Day 1 of a 28-day cycle for evaluation of dose-limiting toxicities and pharmacokinetics. Participants received pembrolizumab IV at a dose of 1 mg/kg every 2 weeks (Q2W) starting with Cycle 2."", ""title_score"": 100, ""desc_score"": 95}]"
NCT01295827,Pembrolizumab,NCT01295827_A2,ORR According to RECIST 1.1 as Assessed by Independent Review Committee (IRC): Non-Small Cell Lung Cancer (NSCLC) Participants (Parts C Plus F),Primary,,[],,,,,[],,[],,,[],,,,,,,,,,O2,Solid Tumors: Pembrolizumab 3 mg/kg Q2W (Part A),During Cycle 1 participants received a dose of 3 mg/kg pembrolizumab IV infusion over 30 minutes on Day 1 of a 28-day cycle for evaluation of dose-limiting toxicities and pharmacokinetics. Participants received pembrolizumab IV at a dose of 3 mg/kg Q2W starting with Cycle 2.,solid tumors pembrolizumab 3 mg kg q2w part a,during cycle 1 participants received a dose of 3 mg kg pembrolizumab iv infusion over 30 minutes on day 1 of a 28 day cycle for evaluation of dose limiting toxicities and pharmacokinetics participants received pembrolizumab iv at a dose of 3 mg kg q2w starting with cycle 2,NCT01295827_A2,Solid Tumors: Pembrolizumab 3 mg/kg Q2W (Part A),During Cycle 1 participants received a dose of 3 mg/kg pembrolizumab IV infusion over 30 minutes on Day 1 of a 28-day cycle for evaluation of dose-limiting toxicities and pharmacokinetics. Participants received pembrolizumab IV at a dose of 3 mg/kg Q2W starting with Cycle 2.,solid tumors pembrolizumab 3 mg kg q2w part a,during cycle 1 participants received a dose of 3 mg kg pembrolizumab iv infusion over 30 minutes on day 1 of a 28 day cycle for evaluation of dose limiting toxicities and pharmacokinetics participants received pembrolizumab iv at a dose of 3 mg kg q2w starting with cycle 2,precise_title,100,100,,"[{""arm_id"": ""NCT01295827_A2"", ""arm_group_title_raw"": ""Solid Tumors: Pembrolizumab 3 mg/kg Q2W (Part A)"", ""arm_group_desc_raw"": ""During Cycle 1 participants received a dose of 3 mg/kg pembrolizumab IV infusion over 30 minutes on Day 1 of a 28-day cycle for evaluation of dose-limiting toxicities and pharmacokinetics. Participants received pembrolizumab IV at a dose of 3 mg/kg Q2W starting with Cycle 2."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT01295827_A3"", ""arm_group_title_raw"": ""Solid Tumors: Pembrolizumab 10 mg/kg Q2W (Parts A+A1)"", ""arm_group_desc_raw"": ""During Cycle 1 participants received a dose of 10 mg/kg pembrolizumab IV infusion over 30 minutes on Day 1 of a 28-day cycle for evaluation of dose-limiting toxicities and pharmacokinetics. Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W starting with Cycle 2."", ""title_score"": 93, ""desc_score"": 99}, {""arm_id"": ""NCT01295827_A1"", ""arm_group_title_raw"": ""Solid Tumors: Pembrolizumab 1 mg/kg Q2W (Part A)"", ""arm_group_desc_raw"": ""During Cycle 1 participants received a dose of 1 mg/kg pembrolizumab intravenous (IV) infusion over 30 minutes on Day 1 of a 28-day cycle for evaluation of dose-limiting toxicities and pharmacokinetics. Participants received pembrolizumab IV at a dose of 1 mg/kg every 2 weeks (Q2W) starting with Cycle 2."", ""title_score"": 98, ""desc_score"": 93}]"
NCT01295827,Pembrolizumab,NCT01295827_A3,ORR According to RECIST 1.1 as Assessed by Independent Review Committee (IRC): Non-Small Cell Lung Cancer (NSCLC) Participants (Parts C Plus F),Primary,,[],,,,,[],,[],,,[],,,,,,,,,,O3,Solid Tumors: Pembrolizumab 10 mg/kg Q2W (Parts A+A1),During Cycle 1 participants received a dose of 10 mg/kg pembrolizumab IV infusion over 30 minutes on Day 1 of a 28-day cycle for evaluation of dose-limiting toxicities and pharmacokinetics. Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W starting with Cycle 2.,solid tumors pembrolizumab 10 mg kg q2w parts a a1,during cycle 1 participants received a dose of 10 mg kg pembrolizumab iv infusion over 30 minutes on day 1 of a 28 day cycle for evaluation of dose limiting toxicities and pharmacokinetics participants received pembrolizumab iv at a dose of 10 mg kg q2w starting with cycle 2,NCT01295827_A3,Solid Tumors: Pembrolizumab 10 mg/kg Q2W (Parts A+A1),During Cycle 1 participants received a dose of 10 mg/kg pembrolizumab IV infusion over 30 minutes on Day 1 of a 28-day cycle for evaluation of dose-limiting toxicities and pharmacokinetics. Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W starting with Cycle 2.,solid tumors pembrolizumab 10 mg kg q2w parts a a1,during cycle 1 participants received a dose of 10 mg kg pembrolizumab iv infusion over 30 minutes on day 1 of a 28 day cycle for evaluation of dose limiting toxicities and pharmacokinetics participants received pembrolizumab iv at a dose of 10 mg kg q2w starting with cycle 2,precise_title,100,100,,"[{""arm_id"": ""NCT01295827_A3"", ""arm_group_title_raw"": ""Solid Tumors: Pembrolizumab 10 mg/kg Q2W (Parts A+A1)"", ""arm_group_desc_raw"": ""During Cycle 1 participants received a dose of 10 mg/kg pembrolizumab IV infusion over 30 minutes on Day 1 of a 28-day cycle for evaluation of dose-limiting toxicities and pharmacokinetics. Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W starting with Cycle 2."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT01295827_A2"", ""arm_group_title_raw"": ""Solid Tumors: Pembrolizumab 3 mg/kg Q2W (Part A)"", ""arm_group_desc_raw"": ""During Cycle 1 participants received a dose of 3 mg/kg pembrolizumab IV infusion over 30 minutes on Day 1 of a 28-day cycle for evaluation of dose-limiting toxicities and pharmacokinetics. Participants received pembrolizumab IV at a dose of 3 mg/kg Q2W starting with Cycle 2."", ""title_score"": 93, ""desc_score"": 99}, {""arm_id"": ""NCT01295827_A1"", ""arm_group_title_raw"": ""Solid Tumors: Pembrolizumab 1 mg/kg Q2W (Part A)"", ""arm_group_desc_raw"": ""During Cycle 1 participants received a dose of 1 mg/kg pembrolizumab intravenous (IV) infusion over 30 minutes on Day 1 of a 28-day cycle for evaluation of dose-limiting toxicities and pharmacokinetics. Participants received pembrolizumab IV at a dose of 1 mg/kg every 2 weeks (Q2W) starting with Cycle 2."", ""title_score"": 95, ""desc_score"": 93}]"
NCT01295827,Pembrolizumab,NCT01295827_A4,ORR According to RECIST 1.1 as Assessed by Independent Review Committee (IRC): Non-Small Cell Lung Cancer (NSCLC) Participants (Parts C Plus F),Primary,,[],,,,,[],,[],,,[],,,,,,,,,,O4,Solid Tumors: Pembrolizumab Titration Cohort 1 Q3W (Part A2),"During Cycle 1 participants received pembrolizumab dose titration from 0.005 mg/kg to 0.3 mg/kg to 2.0 mg/kg on Days 1, 8, and 22, administered as an IV infusion over 30 minutes. Participants received 2 mg/kg every 3 weeks (Q3W) starting with Cycle 2.",solid tumors pembrolizumab titration cohort 1 q3w part a2,during cycle 1 participants received pembrolizumab dose titration from 0 005 mg kg to 0 3 mg kg to 2 0 mg kg on days 1 8 and 22 administered as an iv infusion over 30 minutes participants received 2 mg kg every 3 weeks q3w starting with cycle 2,NCT01295827_A4,Solid Tumors: Pembrolizumab Titration Cohort 1 Q3W (Part A2),"During Cycle 1 participants received pembrolizumab dose titration from 0.005 mg/kg to 0.3 mg/kg to 2.0 mg/kg on Days 1, 8, and 22, administered as an IV infusion over 30 minutes. Participants received 2 mg/kg every 3 weeks (Q3W) starting with Cycle 2.",solid tumors pembrolizumab titration cohort 1 q3w part a2,during cycle 1 participants received pembrolizumab dose titration from 0 005 mg kg to 0 3 mg kg to 2 0 mg kg on days 1 8 and 22 administered as an iv infusion over 30 minutes participants received 2 mg kg every 3 weeks q3w starting with cycle 2,precise_title,100,100,,"[{""arm_id"": ""NCT01295827_A4"", ""arm_group_title_raw"": ""Solid Tumors: Pembrolizumab Titration Cohort 1 Q3W (Part A2)"", ""arm_group_desc_raw"": ""During Cycle 1 participants received pembrolizumab dose titration from 0.005 mg/kg to 0.3 mg/kg to 2.0 mg/kg on Days 1, 8, and 22, administered as an IV infusion over 30 minutes. Participants received 2 mg/kg every 3 weeks (Q3W) starting with Cycle 2."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT01295827_A5"", ""arm_group_title_raw"": ""Solid Tumors: Pembrolizumab Titration Cohort 2 Q3W (Part A2)"", ""arm_group_desc_raw"": ""During Cycle 1 participants received pembrolizumab dose titration from 0.02 mg/kg to 0.3 mg/kg to 2.0 mg/kg on Days 1, 8, and 22, administered as an IV infusion over 30 minutes. Participants received 2 mg/kg Q3W starting with Cycle 2."", ""title_score"": 98, ""desc_score"": 96}, {""arm_id"": ""NCT01295827_A6"", ""arm_group_title_raw"": ""Solid Tumors: Pembrolizumab Titration Cohort 3 Q3W (Part A2)"", ""arm_group_desc_raw"": ""During Cycle 1 participants received pembrolizumab dose titration from 0.06 mg/kg to 1.0 mg/kg to 10 mg/kg on Days 1, 8, and 22, administered as an IV infusion over 30 minutes. Participants received 10 mg/kg Q3W starting with Cycle 2."", ""title_score"": 98, ""desc_score"": 83}]"
NCT01295827,Pembrolizumab,NCT01295827_A5,ORR According to RECIST 1.1 as Assessed by Independent Review Committee (IRC): Non-Small Cell Lung Cancer (NSCLC) Participants (Parts C Plus F),Primary,,[],,,,,[],,[],,,[],,,,,,,,,,O5,Solid Tumors: Pembrolizumab Titration Cohort 2 Q3W (Part A2),"During Cycle 1 participants received pembrolizumab dose titration from 0.02 mg/kg to 0.3 mg/kg to 2.0 mg/kg on Days 1, 8, and 22, administered as an IV infusion over 30 minutes. Participants received 2 mg/kg Q3W starting with Cycle 2.",solid tumors pembrolizumab titration cohort 2 q3w part a2,during cycle 1 participants received pembrolizumab dose titration from 0 02 mg kg to 0 3 mg kg to 2 0 mg kg on days 1 8 and 22 administered as an iv infusion over 30 minutes participants received 2 mg kg q3w starting with cycle 2,NCT01295827_A5,Solid Tumors: Pembrolizumab Titration Cohort 2 Q3W (Part A2),"During Cycle 1 participants received pembrolizumab dose titration from 0.02 mg/kg to 0.3 mg/kg to 2.0 mg/kg on Days 1, 8, and 22, administered as an IV infusion over 30 minutes. Participants received 2 mg/kg Q3W starting with Cycle 2.",solid tumors pembrolizumab titration cohort 2 q3w part a2,during cycle 1 participants received pembrolizumab dose titration from 0 02 mg kg to 0 3 mg kg to 2 0 mg kg on days 1 8 and 22 administered as an iv infusion over 30 minutes participants received 2 mg kg q3w starting with cycle 2,precise_title,100,100,,"[{""arm_id"": ""NCT01295827_A5"", ""arm_group_title_raw"": ""Solid Tumors: Pembrolizumab Titration Cohort 2 Q3W (Part A2)"", ""arm_group_desc_raw"": ""During Cycle 1 participants received pembrolizumab dose titration from 0.02 mg/kg to 0.3 mg/kg to 2.0 mg/kg on Days 1, 8, and 22, administered as an IV infusion over 30 minutes. Participants received 2 mg/kg Q3W starting with Cycle 2."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT01295827_A4"", ""arm_group_title_raw"": ""Solid Tumors: Pembrolizumab Titration Cohort 1 Q3W (Part A2)"", ""arm_group_desc_raw"": ""During Cycle 1 participants received pembrolizumab dose titration from 0.005 mg/kg to 0.3 mg/kg to 2.0 mg/kg on Days 1, 8, and 22, administered as an IV infusion over 30 minutes. Participants received 2 mg/kg every 3 weeks (Q3W) starting with Cycle 2."", ""title_score"": 98, ""desc_score"": 96}, {""arm_id"": ""NCT01295827_A6"", ""arm_group_title_raw"": ""Solid Tumors: Pembrolizumab Titration Cohort 3 Q3W (Part A2)"", ""arm_group_desc_raw"": ""During Cycle 1 participants received pembrolizumab dose titration from 0.06 mg/kg to 1.0 mg/kg to 10 mg/kg on Days 1, 8, and 22, administered as an IV infusion over 30 minutes. Participants received 10 mg/kg Q3W starting with Cycle 2."", ""title_score"": 98, ""desc_score"": 88}]"
NCT01295827,Pembrolizumab,NCT01295827_A6,ORR According to RECIST 1.1 as Assessed by Independent Review Committee (IRC): Non-Small Cell Lung Cancer (NSCLC) Participants (Parts C Plus F),Primary,,[],,,,,[],,[],,,[],,,,,,,,,,O6,Solid Tumors: Pembrolizumab Titration Cohort 3 Q3W (Part A2),"During Cycle 1 participants received pembrolizumab dose titration from 0.06 mg/kg to 1.0 mg/kg to 10 mg/kg on Days 1, 8, and 22, administered as an IV infusion over 30 minutes. Participants received 10 mg/kg Q3W starting with Cycle 2.",solid tumors pembrolizumab titration cohort 3 q3w part a2,during cycle 1 participants received pembrolizumab dose titration from 0 06 mg kg to 1 0 mg kg to 10 mg kg on days 1 8 and 22 administered as an iv infusion over 30 minutes participants received 10 mg kg q3w starting with cycle 2,NCT01295827_A6,Solid Tumors: Pembrolizumab Titration Cohort 3 Q3W (Part A2),"During Cycle 1 participants received pembrolizumab dose titration from 0.06 mg/kg to 1.0 mg/kg to 10 mg/kg on Days 1, 8, and 22, administered as an IV infusion over 30 minutes. Participants received 10 mg/kg Q3W starting with Cycle 2.",solid tumors pembrolizumab titration cohort 3 q3w part a2,during cycle 1 participants received pembrolizumab dose titration from 0 06 mg kg to 1 0 mg kg to 10 mg kg on days 1 8 and 22 administered as an iv infusion over 30 minutes participants received 10 mg kg q3w starting with cycle 2,precise_title,100,100,,"[{""arm_id"": ""NCT01295827_A6"", ""arm_group_title_raw"": ""Solid Tumors: Pembrolizumab Titration Cohort 3 Q3W (Part A2)"", ""arm_group_desc_raw"": ""During Cycle 1 participants received pembrolizumab dose titration from 0.06 mg/kg to 1.0 mg/kg to 10 mg/kg on Days 1, 8, and 22, administered as an IV infusion over 30 minutes. Participants received 10 mg/kg Q3W starting with Cycle 2."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT01295827_A5"", ""arm_group_title_raw"": ""Solid Tumors: Pembrolizumab Titration Cohort 2 Q3W (Part A2)"", ""arm_group_desc_raw"": ""During Cycle 1 participants received pembrolizumab dose titration from 0.02 mg/kg to 0.3 mg/kg to 2.0 mg/kg on Days 1, 8, and 22, administered as an IV infusion over 30 minutes. Participants received 2 mg/kg Q3W starting with Cycle 2."", ""title_score"": 98, ""desc_score"": 82}, {""arm_id"": ""NCT01295827_A4"", ""arm_group_title_raw"": ""Solid Tumors: Pembrolizumab Titration Cohort 1 Q3W (Part A2)"", ""arm_group_desc_raw"": ""During Cycle 1 participants received pembrolizumab dose titration from 0.005 mg/kg to 0.3 mg/kg to 2.0 mg/kg on Days 1, 8, and 22, administered as an IV infusion over 30 minutes. Participants received 2 mg/kg every 3 weeks (Q3W) starting with Cycle 2."", ""title_score"": 98, ""desc_score"": 77}]"
NCT01295827,Pembrolizumab,NCT01295827_A7,ORR According to RECIST 1.1 as Assessed by Independent Review Committee (IRC): Non-Small Cell Lung Cancer (NSCLC) Participants (Parts C Plus F),Primary,,[],,,,,[],,[],,,[],,,,,,,,,,O7,MEL: Pembrolizumab 2 mg/kg Q3W (Parts B+D),"Participants received pembrolizumab IV at a dose of 2 mg/kg Q2W. After Amendment 3, participants received dosing Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data.",mel pembrolizumab 2 mg kg q3w parts b d,participants received pembrolizumab iv at a dose of 2 mg kg q2w after amendment 3 participants received dosing q3w after amendment 10 all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab iv q3w based on analysis of safety and efficacy data,NCT01295827_A7,MEL: Pembrolizumab 2 mg/kg Q3W (Parts B+D),"Participants received pembrolizumab IV at a dose of 2 mg/kg Q2W. After Amendment 3, participants received dosing Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data.",mel pembrolizumab 2 mg kg q3w parts b d,participants received pembrolizumab iv at a dose of 2 mg kg q2w after amendment 3 participants received dosing q3w after amendment 10 all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab iv q3w based on analysis of safety and efficacy data,precise_title,100,100,,"[{""arm_id"": ""NCT01295827_A7"", ""arm_group_title_raw"": ""MEL: Pembrolizumab 2 mg/kg Q3W (Parts B+D)"", ""arm_group_desc_raw"": ""Participants received pembrolizumab IV at a dose of 2 mg/kg Q2W. After Amendment 3, participants received dosing Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT01295827_A8"", ""arm_group_title_raw"": ""MEL: Pembrolizumab 10 mg/kg Q3W (Parts B+D)"", ""arm_group_desc_raw"": ""Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W. After Amendment 7, participants received dosing Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data."", ""title_score"": 96, ""desc_score"": 99}, {""arm_id"": ""NCT01295827_A10"", ""arm_group_title_raw"": ""NSCLC: Pembrolizumab 2 mg/kg Q3W (Part F)"", ""arm_group_desc_raw"": ""Participants received pembrolizumab IV at a dose of 2 mg/kg Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data."", ""title_score"": 86, ""desc_score"": 90}]"
NCT01295827,Pembrolizumab,NCT01295827_A8,ORR According to RECIST 1.1 as Assessed by Independent Review Committee (IRC): Non-Small Cell Lung Cancer (NSCLC) Participants (Parts C Plus F),Primary,,[],,,,,[],,[],,,[],,,,,,,,,,O8,MEL: Pembrolizumab 10 mg/kg Q3W (Parts B+D),"Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W. After Amendment 7, participants received dosing Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data.",mel pembrolizumab 10 mg kg q3w parts b d,participants received pembrolizumab iv at a dose of 10 mg kg q2w after amendment 7 participants received dosing q3w after amendment 10 all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab iv q3w based on analysis of safety and efficacy data,NCT01295827_A8,MEL: Pembrolizumab 10 mg/kg Q3W (Parts B+D),"Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W. After Amendment 7, participants received dosing Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data.",mel pembrolizumab 10 mg kg q3w parts b d,participants received pembrolizumab iv at a dose of 10 mg kg q2w after amendment 7 participants received dosing q3w after amendment 10 all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab iv q3w based on analysis of safety and efficacy data,precise_title,100,100,,"[{""arm_id"": ""NCT01295827_A8"", ""arm_group_title_raw"": ""MEL: Pembrolizumab 10 mg/kg Q3W (Parts B+D)"", ""arm_group_desc_raw"": ""Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W. After Amendment 7, participants received dosing Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT01295827_A7"", ""arm_group_title_raw"": ""MEL: Pembrolizumab 2 mg/kg Q3W (Parts B+D)"", ""arm_group_desc_raw"": ""Participants received pembrolizumab IV at a dose of 2 mg/kg Q2W. After Amendment 3, participants received dosing Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data."", ""title_score"": 96, ""desc_score"": 99}, {""arm_id"": ""NCT01295827_A10"", ""arm_group_title_raw"": ""NSCLC: Pembrolizumab 2 mg/kg Q3W (Part F)"", ""arm_group_desc_raw"": ""Participants received pembrolizumab IV at a dose of 2 mg/kg Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data."", ""title_score"": 82, ""desc_score"": 89}]"
NCT01295827,Pembrolizumab,NCT01295827_A9,ORR According to RECIST 1.1 as Assessed by Independent Review Committee (IRC): Non-Small Cell Lung Cancer (NSCLC) Participants (Parts C Plus F),Primary,,[],,,,,[],,[],,,[],,,,,,,,,,O9,MEL: Pembrolizumab 10 mg/kg Q2W (Part B),"Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data.",mel pembrolizumab 10 mg kg q2w part b,participants received pembrolizumab iv at a dose of 10 mg kg q2w after amendment 10 all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab iv q3w based on analysis of safety and efficacy data,NCT01295827_A9,MEL: Pembrolizumab 10 mg/kg Q2W (Part B),"Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data.",mel pembrolizumab 10 mg kg q2w part b,participants received pembrolizumab iv at a dose of 10 mg kg q2w after amendment 10 all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab iv q3w based on analysis of safety and efficacy data,precise_title,100,100,,"[{""arm_id"": ""NCT01295827_A9"", ""arm_group_title_raw"": ""MEL: Pembrolizumab 10 mg/kg Q2W (Part B)"", ""arm_group_desc_raw"": ""Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT01295827_A12"", ""arm_group_title_raw"": ""NSCLC: Pembrolizumab 10 mg/kg Q2W (Part F)"", ""arm_group_desc_raw"": ""Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data."", ""title_score"": 89, ""desc_score"": 100}, {""arm_id"": ""NCT01295827_A11"", ""arm_group_title_raw"": ""NSCLC: Pembrolizumab 10 mg/kg Q3W (Parts C+F)"", ""arm_group_desc_raw"": ""Participants received pembrolizumab IV at a dose of 10 mg/kg Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data."", ""title_score"": 84, ""desc_score"": 100}]"
NCT01295827,Pembrolizumab,NCT01295827_A10,ORR According to RECIST 1.1 as Assessed by Independent Review Committee (IRC): Non-Small Cell Lung Cancer (NSCLC) Participants (Parts C Plus F),Primary,,[],,,,,"[{""measure_title"": ""ORR According to RECIST 1.1 as Assessed by Independent Review Committee (IRC): Non-Small Cell Lung Cancer (NSCLC) Participants (Parts C Plus F)"", ""units"": ""Percentage of Participants"", ""param"": ""Number"", ""dispersion"": ""95% Confidence Interval"", ""values"": [{""group_id"": ""O10"", ""value"": ""19.7"", ""lower"": ""10.6"", ""upper"": ""31.8""}]}]",Percentage of Participants,[],,,[],,,,,,,,,,O10,NSCLC: Pembrolizumab 2 mg/kg Q3W (Part F),"Participants received pembrolizumab IV at a dose of 2 mg/kg Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data.",nsclc pembrolizumab 2 mg kg q3w part f,participants received pembrolizumab iv at a dose of 2 mg kg q3w after amendment 10 all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab iv q3w based on analysis of safety and efficacy data,NCT01295827_A10,NSCLC: Pembrolizumab 2 mg/kg Q3W (Part F),"Participants received pembrolizumab IV at a dose of 2 mg/kg Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data.",nsclc pembrolizumab 2 mg kg q3w part f,participants received pembrolizumab iv at a dose of 2 mg kg q3w after amendment 10 all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab iv q3w based on analysis of safety and efficacy data,precise_title,100,100,,"[{""arm_id"": ""NCT01295827_A10"", ""arm_group_title_raw"": ""NSCLC: Pembrolizumab 2 mg/kg Q3W (Part F)"", ""arm_group_desc_raw"": ""Participants received pembrolizumab IV at a dose of 2 mg/kg Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT01295827_A11"", ""arm_group_title_raw"": ""NSCLC: Pembrolizumab 10 mg/kg Q3W (Parts C+F)"", ""arm_group_desc_raw"": ""Participants received pembrolizumab IV at a dose of 10 mg/kg Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data."", ""title_score"": 92, ""desc_score"": 99}, {""arm_id"": ""NCT01295827_A7"", ""arm_group_title_raw"": ""MEL: Pembrolizumab 2 mg/kg Q3W (Parts B+D)"", ""arm_group_desc_raw"": ""Participants received pembrolizumab IV at a dose of 2 mg/kg Q2W. After Amendment 3, participants received dosing Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data."", ""title_score"": 86, ""desc_score"": 90}]"
NCT01295827,Pembrolizumab,NCT01295827_A11,ORR According to RECIST 1.1 as Assessed by Independent Review Committee (IRC): Non-Small Cell Lung Cancer (NSCLC) Participants (Parts C Plus F),Primary,,[],,,,,"[{""measure_title"": ""ORR According to RECIST 1.1 as Assessed by Independent Review Committee (IRC): Non-Small Cell Lung Cancer (NSCLC) Participants (Parts C Plus F)"", ""units"": ""Percentage of Participants"", ""param"": ""Number"", ""dispersion"": ""95% Confidence Interval"", ""values"": [{""group_id"": ""O11"", ""value"": ""21.6"", ""lower"": ""17.0"", ""upper"": ""26.8""}]}]",Percentage of Participants,[],,,[],,,,,,,,,,O11,NSCLC: Pembrolizumab 10 mg/kg Q3W (Parts C+F),"Participants received pembrolizumab IV at a dose of 10 mg/kg Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data.",nsclc pembrolizumab 10 mg kg q3w parts c f,participants received pembrolizumab iv at a dose of 10 mg kg q3w after amendment 10 all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab iv q3w based on analysis of safety and efficacy data,NCT01295827_A11,NSCLC: Pembrolizumab 10 mg/kg Q3W (Parts C+F),"Participants received pembrolizumab IV at a dose of 10 mg/kg Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data.",nsclc pembrolizumab 10 mg kg q3w parts c f,participants received pembrolizumab iv at a dose of 10 mg kg q3w after amendment 10 all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab iv q3w based on analysis of safety and efficacy data,precise_title,100,100,,"[{""arm_id"": ""NCT01295827_A11"", ""arm_group_title_raw"": ""NSCLC: Pembrolizumab 10 mg/kg Q3W (Parts C+F)"", ""arm_group_desc_raw"": ""Participants received pembrolizumab IV at a dose of 10 mg/kg Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT01295827_A12"", ""arm_group_title_raw"": ""NSCLC: Pembrolizumab 10 mg/kg Q2W (Part F)"", ""arm_group_desc_raw"": ""Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data."", ""title_score"": 94, ""desc_score"": 100}, {""arm_id"": ""NCT01295827_A9"", ""arm_group_title_raw"": ""MEL: Pembrolizumab 10 mg/kg Q2W (Part B)"", ""arm_group_desc_raw"": ""Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data."", ""title_score"": 84, ""desc_score"": 100}]"
NCT01295827,Pembrolizumab,NCT01295827_A12,ORR According to RECIST 1.1 as Assessed by Independent Review Committee (IRC): Non-Small Cell Lung Cancer (NSCLC) Participants (Parts C Plus F),Primary,,[],,,,,"[{""measure_title"": ""ORR According to RECIST 1.1 as Assessed by Independent Review Committee (IRC): Non-Small Cell Lung Cancer (NSCLC) Participants (Parts C Plus F)"", ""units"": ""Percentage of Participants"", ""param"": ""Number"", ""dispersion"": ""95% Confidence Interval"", ""values"": [{""group_id"": ""O12"", ""value"": ""19.3"", ""lower"": ""14.1"", ""upper"": ""25.4""}]}]",Percentage of Participants,[],,,[],,,,,,,,,,O12,NSCLC: Pembrolizumab 10 mg/kg Q2W (Part F),"Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data.",nsclc pembrolizumab 10 mg kg q2w part f,participants received pembrolizumab iv at a dose of 10 mg kg q2w after amendment 10 all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab iv q3w based on analysis of safety and efficacy data,NCT01295827_A12,NSCLC: Pembrolizumab 10 mg/kg Q2W (Part F),"Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data.",nsclc pembrolizumab 10 mg kg q2w part f,participants received pembrolizumab iv at a dose of 10 mg kg q2w after amendment 10 all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab iv q3w based on analysis of safety and efficacy data,precise_title,100,100,,"[{""arm_id"": ""NCT01295827_A12"", ""arm_group_title_raw"": ""NSCLC: Pembrolizumab 10 mg/kg Q2W (Part F)"", ""arm_group_desc_raw"": ""Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT01295827_A11"", ""arm_group_title_raw"": ""NSCLC: Pembrolizumab 10 mg/kg Q3W (Parts C+F)"", ""arm_group_desc_raw"": ""Participants received pembrolizumab IV at a dose of 10 mg/kg Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data."", ""title_score"": 94, ""desc_score"": 100}, {""arm_id"": ""NCT01295827_A9"", ""arm_group_title_raw"": ""MEL: Pembrolizumab 10 mg/kg Q2W (Part B)"", ""arm_group_desc_raw"": ""Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data."", ""title_score"": 89, ""desc_score"": 100}]"
NCT01295827,Pembrolizumab,NCT01295827_A1,ORR According to Immune-related Response Criteria (irRC) as Assessed by Investigator in Melanoma Participants (Parts B Plus D),Key Secondary,,[],,,,,[],,[],,,[],,,,,,,,,,O1,Solid Tumors: Pembrolizumab 1 mg/kg Q2W (Part A),During Cycle 1 participants received a dose of 1 mg/kg pembrolizumab IV infusion over 30 minutes on Day 1 of a 28-day cycle for evaluation of dose-limiting toxicities and pharmacokinetics. Participants received pembrolizumab IV at a dose of 1 mg/kg Q2W starting with Cycle 2.,solid tumors pembrolizumab 1 mg kg q2w part a,during cycle 1 participants received a dose of 1 mg kg pembrolizumab iv infusion over 30 minutes on day 1 of a 28 day cycle for evaluation of dose limiting toxicities and pharmacokinetics participants received pembrolizumab iv at a dose of 1 mg kg q2w starting with cycle 2,NCT01295827_A1,Solid Tumors: Pembrolizumab 1 mg/kg Q2W (Part A),During Cycle 1 participants received a dose of 1 mg/kg pembrolizumab intravenous (IV) infusion over 30 minutes on Day 1 of a 28-day cycle for evaluation of dose-limiting toxicities and pharmacokinetics. Participants received pembrolizumab IV at a dose of 1 mg/kg every 2 weeks (Q2W) starting with Cycle 2.,solid tumors pembrolizumab 1 mg kg q2w part a,during cycle 1 participants received a dose of 1 mg kg pembrolizumab intravenous iv infusion over 30 minutes on day 1 of a 28 day cycle for evaluation of dose limiting toxicities and pharmacokinetics participants received pembrolizumab iv at a dose of 1 mg kg every 2 weeks q2w starting with cycle 2,precise_title,100,95,,"[{""arm_id"": ""NCT01295827_A3"", ""arm_group_title_raw"": ""Solid Tumors: Pembrolizumab 10 mg/kg Q2W (Parts A+A1)"", ""arm_group_desc_raw"": ""During Cycle 1 participants received a dose of 10 mg/kg pembrolizumab IV infusion over 30 minutes on Day 1 of a 28-day cycle for evaluation of dose-limiting toxicities and pharmacokinetics. Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W starting with Cycle 2."", ""title_score"": 95, ""desc_score"": 100}, {""arm_id"": ""NCT01295827_A2"", ""arm_group_title_raw"": ""Solid Tumors: Pembrolizumab 3 mg/kg Q2W (Part A)"", ""arm_group_desc_raw"": ""During Cycle 1 participants received a dose of 3 mg/kg pembrolizumab IV infusion over 30 minutes on Day 1 of a 28-day cycle for evaluation of dose-limiting toxicities and pharmacokinetics. Participants received pembrolizumab IV at a dose of 3 mg/kg Q2W starting with Cycle 2."", ""title_score"": 98, ""desc_score"": 99}, {""arm_id"": ""NCT01295827_A1"", ""arm_group_title_raw"": ""Solid Tumors: Pembrolizumab 1 mg/kg Q2W (Part A)"", ""arm_group_desc_raw"": ""During Cycle 1 participants received a dose of 1 mg/kg pembrolizumab intravenous (IV) infusion over 30 minutes on Day 1 of a 28-day cycle for evaluation of dose-limiting toxicities and pharmacokinetics. Participants received pembrolizumab IV at a dose of 1 mg/kg every 2 weeks (Q2W) starting with Cycle 2."", ""title_score"": 100, ""desc_score"": 95}]"
NCT01295827,Pembrolizumab,NCT01295827_A2,ORR According to Immune-related Response Criteria (irRC) as Assessed by Investigator in Melanoma Participants (Parts B Plus D),Key Secondary,,[],,,,,[],,[],,,[],,,,,,,,,,O2,Solid Tumors: Pembrolizumab 3 mg/kg Q2W (Part A),During Cycle 1 participants received a dose of 3 mg/kg pembrolizumab IV infusion over 30 minutes on Day 1 of a 28-day cycle for evaluation of dose-limiting toxicities and pharmacokinetics. Participants received pembrolizumab IV at a dose of 3 mg/kg Q2W starting with Cycle 2.,solid tumors pembrolizumab 3 mg kg q2w part a,during cycle 1 participants received a dose of 3 mg kg pembrolizumab iv infusion over 30 minutes on day 1 of a 28 day cycle for evaluation of dose limiting toxicities and pharmacokinetics participants received pembrolizumab iv at a dose of 3 mg kg q2w starting with cycle 2,NCT01295827_A2,Solid Tumors: Pembrolizumab 3 mg/kg Q2W (Part A),During Cycle 1 participants received a dose of 3 mg/kg pembrolizumab IV infusion over 30 minutes on Day 1 of a 28-day cycle for evaluation of dose-limiting toxicities and pharmacokinetics. Participants received pembrolizumab IV at a dose of 3 mg/kg Q2W starting with Cycle 2.,solid tumors pembrolizumab 3 mg kg q2w part a,during cycle 1 participants received a dose of 3 mg kg pembrolizumab iv infusion over 30 minutes on day 1 of a 28 day cycle for evaluation of dose limiting toxicities and pharmacokinetics participants received pembrolizumab iv at a dose of 3 mg kg q2w starting with cycle 2,precise_title,100,100,,"[{""arm_id"": ""NCT01295827_A2"", ""arm_group_title_raw"": ""Solid Tumors: Pembrolizumab 3 mg/kg Q2W (Part A)"", ""arm_group_desc_raw"": ""During Cycle 1 participants received a dose of 3 mg/kg pembrolizumab IV infusion over 30 minutes on Day 1 of a 28-day cycle for evaluation of dose-limiting toxicities and pharmacokinetics. Participants received pembrolizumab IV at a dose of 3 mg/kg Q2W starting with Cycle 2."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT01295827_A3"", ""arm_group_title_raw"": ""Solid Tumors: Pembrolizumab 10 mg/kg Q2W (Parts A+A1)"", ""arm_group_desc_raw"": ""During Cycle 1 participants received a dose of 10 mg/kg pembrolizumab IV infusion over 30 minutes on Day 1 of a 28-day cycle for evaluation of dose-limiting toxicities and pharmacokinetics. Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W starting with Cycle 2."", ""title_score"": 93, ""desc_score"": 99}, {""arm_id"": ""NCT01295827_A1"", ""arm_group_title_raw"": ""Solid Tumors: Pembrolizumab 1 mg/kg Q2W (Part A)"", ""arm_group_desc_raw"": ""During Cycle 1 participants received a dose of 1 mg/kg pembrolizumab intravenous (IV) infusion over 30 minutes on Day 1 of a 28-day cycle for evaluation of dose-limiting toxicities and pharmacokinetics. Participants received pembrolizumab IV at a dose of 1 mg/kg every 2 weeks (Q2W) starting with Cycle 2."", ""title_score"": 98, ""desc_score"": 93}]"
NCT01295827,Pembrolizumab,NCT01295827_A3,ORR According to Immune-related Response Criteria (irRC) as Assessed by Investigator in Melanoma Participants (Parts B Plus D),Key Secondary,,[],,,,,[],,[],,,[],,,,,,,,,,O3,Solid Tumors: Pembrolizumab 10 mg/kg Q2W (Parts A+A1),During Cycle 1 participants received a dose of 10 mg/kg pembrolizumab IV infusion over 30 minutes on Day 1 of a 28-day cycle for evaluation of dose-limiting toxicities and pharmacokinetics. Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W starting with Cycle 2.,solid tumors pembrolizumab 10 mg kg q2w parts a a1,during cycle 1 participants received a dose of 10 mg kg pembrolizumab iv infusion over 30 minutes on day 1 of a 28 day cycle for evaluation of dose limiting toxicities and pharmacokinetics participants received pembrolizumab iv at a dose of 10 mg kg q2w starting with cycle 2,NCT01295827_A3,Solid Tumors: Pembrolizumab 10 mg/kg Q2W (Parts A+A1),During Cycle 1 participants received a dose of 10 mg/kg pembrolizumab IV infusion over 30 minutes on Day 1 of a 28-day cycle for evaluation of dose-limiting toxicities and pharmacokinetics. Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W starting with Cycle 2.,solid tumors pembrolizumab 10 mg kg q2w parts a a1,during cycle 1 participants received a dose of 10 mg kg pembrolizumab iv infusion over 30 minutes on day 1 of a 28 day cycle for evaluation of dose limiting toxicities and pharmacokinetics participants received pembrolizumab iv at a dose of 10 mg kg q2w starting with cycle 2,precise_title,100,100,,"[{""arm_id"": ""NCT01295827_A3"", ""arm_group_title_raw"": ""Solid Tumors: Pembrolizumab 10 mg/kg Q2W (Parts A+A1)"", ""arm_group_desc_raw"": ""During Cycle 1 participants received a dose of 10 mg/kg pembrolizumab IV infusion over 30 minutes on Day 1 of a 28-day cycle for evaluation of dose-limiting toxicities and pharmacokinetics. Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W starting with Cycle 2."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT01295827_A2"", ""arm_group_title_raw"": ""Solid Tumors: Pembrolizumab 3 mg/kg Q2W (Part A)"", ""arm_group_desc_raw"": ""During Cycle 1 participants received a dose of 3 mg/kg pembrolizumab IV infusion over 30 minutes on Day 1 of a 28-day cycle for evaluation of dose-limiting toxicities and pharmacokinetics. Participants received pembrolizumab IV at a dose of 3 mg/kg Q2W starting with Cycle 2."", ""title_score"": 93, ""desc_score"": 99}, {""arm_id"": ""NCT01295827_A1"", ""arm_group_title_raw"": ""Solid Tumors: Pembrolizumab 1 mg/kg Q2W (Part A)"", ""arm_group_desc_raw"": ""During Cycle 1 participants received a dose of 1 mg/kg pembrolizumab intravenous (IV) infusion over 30 minutes on Day 1 of a 28-day cycle for evaluation of dose-limiting toxicities and pharmacokinetics. Participants received pembrolizumab IV at a dose of 1 mg/kg every 2 weeks (Q2W) starting with Cycle 2."", ""title_score"": 95, ""desc_score"": 93}]"
NCT01295827,Pembrolizumab,NCT01295827_A4,ORR According to Immune-related Response Criteria (irRC) as Assessed by Investigator in Melanoma Participants (Parts B Plus D),Key Secondary,,[],,,,,[],,[],,,[],,,,,,,,,,O4,Solid Tumors: Pembrolizumab Titration Cohort 1 Q3W (Part A2),"During Cycle 1 participants received pembrolizumab dose titration from 0.005 mg/kg to 0.3 mg/kg to 2.0 mg/kg on Days 1, 8, and 22, administered as an IV infusion over 30 minutes. Participants received 2 mg/kg every 3 weeks (Q3W) starting with Cycle 2.",solid tumors pembrolizumab titration cohort 1 q3w part a2,during cycle 1 participants received pembrolizumab dose titration from 0 005 mg kg to 0 3 mg kg to 2 0 mg kg on days 1 8 and 22 administered as an iv infusion over 30 minutes participants received 2 mg kg every 3 weeks q3w starting with cycle 2,NCT01295827_A4,Solid Tumors: Pembrolizumab Titration Cohort 1 Q3W (Part A2),"During Cycle 1 participants received pembrolizumab dose titration from 0.005 mg/kg to 0.3 mg/kg to 2.0 mg/kg on Days 1, 8, and 22, administered as an IV infusion over 30 minutes. Participants received 2 mg/kg every 3 weeks (Q3W) starting with Cycle 2.",solid tumors pembrolizumab titration cohort 1 q3w part a2,during cycle 1 participants received pembrolizumab dose titration from 0 005 mg kg to 0 3 mg kg to 2 0 mg kg on days 1 8 and 22 administered as an iv infusion over 30 minutes participants received 2 mg kg every 3 weeks q3w starting with cycle 2,precise_title,100,100,,"[{""arm_id"": ""NCT01295827_A4"", ""arm_group_title_raw"": ""Solid Tumors: Pembrolizumab Titration Cohort 1 Q3W (Part A2)"", ""arm_group_desc_raw"": ""During Cycle 1 participants received pembrolizumab dose titration from 0.005 mg/kg to 0.3 mg/kg to 2.0 mg/kg on Days 1, 8, and 22, administered as an IV infusion over 30 minutes. Participants received 2 mg/kg every 3 weeks (Q3W) starting with Cycle 2."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT01295827_A5"", ""arm_group_title_raw"": ""Solid Tumors: Pembrolizumab Titration Cohort 2 Q3W (Part A2)"", ""arm_group_desc_raw"": ""During Cycle 1 participants received pembrolizumab dose titration from 0.02 mg/kg to 0.3 mg/kg to 2.0 mg/kg on Days 1, 8, and 22, administered as an IV infusion over 30 minutes. Participants received 2 mg/kg Q3W starting with Cycle 2."", ""title_score"": 98, ""desc_score"": 96}, {""arm_id"": ""NCT01295827_A6"", ""arm_group_title_raw"": ""Solid Tumors: Pembrolizumab Titration Cohort 3 Q3W (Part A2)"", ""arm_group_desc_raw"": ""During Cycle 1 participants received pembrolizumab dose titration from 0.06 mg/kg to 1.0 mg/kg to 10 mg/kg on Days 1, 8, and 22, administered as an IV infusion over 30 minutes. Participants received 10 mg/kg Q3W starting with Cycle 2."", ""title_score"": 98, ""desc_score"": 83}]"
NCT01295827,Pembrolizumab,NCT01295827_A5,ORR According to Immune-related Response Criteria (irRC) as Assessed by Investigator in Melanoma Participants (Parts B Plus D),Key Secondary,,[],,,,,[],,[],,,[],,,,,,,,,,O5,Solid Tumors: Pembrolizumab Titration Cohort 2 Q3W (Part A2),"During Cycle 1 participants received pembrolizumab dose titration from 0.02 mg/kg to 0.3 mg/kg to 2.0 mg/kg on Days 1, 8, and 22, administered as an IV infusion over 30 minutes. Participants received 2 mg/kg Q3W starting with Cycle 2.",solid tumors pembrolizumab titration cohort 2 q3w part a2,during cycle 1 participants received pembrolizumab dose titration from 0 02 mg kg to 0 3 mg kg to 2 0 mg kg on days 1 8 and 22 administered as an iv infusion over 30 minutes participants received 2 mg kg q3w starting with cycle 2,NCT01295827_A5,Solid Tumors: Pembrolizumab Titration Cohort 2 Q3W (Part A2),"During Cycle 1 participants received pembrolizumab dose titration from 0.02 mg/kg to 0.3 mg/kg to 2.0 mg/kg on Days 1, 8, and 22, administered as an IV infusion over 30 minutes. Participants received 2 mg/kg Q3W starting with Cycle 2.",solid tumors pembrolizumab titration cohort 2 q3w part a2,during cycle 1 participants received pembrolizumab dose titration from 0 02 mg kg to 0 3 mg kg to 2 0 mg kg on days 1 8 and 22 administered as an iv infusion over 30 minutes participants received 2 mg kg q3w starting with cycle 2,precise_title,100,100,,"[{""arm_id"": ""NCT01295827_A5"", ""arm_group_title_raw"": ""Solid Tumors: Pembrolizumab Titration Cohort 2 Q3W (Part A2)"", ""arm_group_desc_raw"": ""During Cycle 1 participants received pembrolizumab dose titration from 0.02 mg/kg to 0.3 mg/kg to 2.0 mg/kg on Days 1, 8, and 22, administered as an IV infusion over 30 minutes. Participants received 2 mg/kg Q3W starting with Cycle 2."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT01295827_A4"", ""arm_group_title_raw"": ""Solid Tumors: Pembrolizumab Titration Cohort 1 Q3W (Part A2)"", ""arm_group_desc_raw"": ""During Cycle 1 participants received pembrolizumab dose titration from 0.005 mg/kg to 0.3 mg/kg to 2.0 mg/kg on Days 1, 8, and 22, administered as an IV infusion over 30 minutes. Participants received 2 mg/kg every 3 weeks (Q3W) starting with Cycle 2."", ""title_score"": 98, ""desc_score"": 96}, {""arm_id"": ""NCT01295827_A6"", ""arm_group_title_raw"": ""Solid Tumors: Pembrolizumab Titration Cohort 3 Q3W (Part A2)"", ""arm_group_desc_raw"": ""During Cycle 1 participants received pembrolizumab dose titration from 0.06 mg/kg to 1.0 mg/kg to 10 mg/kg on Days 1, 8, and 22, administered as an IV infusion over 30 minutes. Participants received 10 mg/kg Q3W starting with Cycle 2."", ""title_score"": 98, ""desc_score"": 88}]"
NCT01295827,Pembrolizumab,NCT01295827_A6,ORR According to Immune-related Response Criteria (irRC) as Assessed by Investigator in Melanoma Participants (Parts B Plus D),Key Secondary,,[],,,,,[],,[],,,[],,,,,,,,,,O6,Solid Tumors: Pembrolizumab Titration Cohort 3 Q3W (Part A2),"During Cycle 1 participants received pembrolizumab dose titration from 0.06 mg/kg to 1.0 mg/kg to 10 mg/kg on Days 1, 8, and 22, administered as an IV infusion over 30 minutes. Participants received 10 mg/kg Q3W starting with Cycle 2.",solid tumors pembrolizumab titration cohort 3 q3w part a2,during cycle 1 participants received pembrolizumab dose titration from 0 06 mg kg to 1 0 mg kg to 10 mg kg on days 1 8 and 22 administered as an iv infusion over 30 minutes participants received 10 mg kg q3w starting with cycle 2,NCT01295827_A6,Solid Tumors: Pembrolizumab Titration Cohort 3 Q3W (Part A2),"During Cycle 1 participants received pembrolizumab dose titration from 0.06 mg/kg to 1.0 mg/kg to 10 mg/kg on Days 1, 8, and 22, administered as an IV infusion over 30 minutes. Participants received 10 mg/kg Q3W starting with Cycle 2.",solid tumors pembrolizumab titration cohort 3 q3w part a2,during cycle 1 participants received pembrolizumab dose titration from 0 06 mg kg to 1 0 mg kg to 10 mg kg on days 1 8 and 22 administered as an iv infusion over 30 minutes participants received 10 mg kg q3w starting with cycle 2,precise_title,100,100,,"[{""arm_id"": ""NCT01295827_A6"", ""arm_group_title_raw"": ""Solid Tumors: Pembrolizumab Titration Cohort 3 Q3W (Part A2)"", ""arm_group_desc_raw"": ""During Cycle 1 participants received pembrolizumab dose titration from 0.06 mg/kg to 1.0 mg/kg to 10 mg/kg on Days 1, 8, and 22, administered as an IV infusion over 30 minutes. Participants received 10 mg/kg Q3W starting with Cycle 2."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT01295827_A5"", ""arm_group_title_raw"": ""Solid Tumors: Pembrolizumab Titration Cohort 2 Q3W (Part A2)"", ""arm_group_desc_raw"": ""During Cycle 1 participants received pembrolizumab dose titration from 0.02 mg/kg to 0.3 mg/kg to 2.0 mg/kg on Days 1, 8, and 22, administered as an IV infusion over 30 minutes. Participants received 2 mg/kg Q3W starting with Cycle 2."", ""title_score"": 98, ""desc_score"": 82}, {""arm_id"": ""NCT01295827_A4"", ""arm_group_title_raw"": ""Solid Tumors: Pembrolizumab Titration Cohort 1 Q3W (Part A2)"", ""arm_group_desc_raw"": ""During Cycle 1 participants received pembrolizumab dose titration from 0.005 mg/kg to 0.3 mg/kg to 2.0 mg/kg on Days 1, 8, and 22, administered as an IV infusion over 30 minutes. Participants received 2 mg/kg every 3 weeks (Q3W) starting with Cycle 2."", ""title_score"": 98, ""desc_score"": 77}]"
NCT01295827,Pembrolizumab,NCT01295827_A7,ORR According to Immune-related Response Criteria (irRC) as Assessed by Investigator in Melanoma Participants (Parts B Plus D),Key Secondary,,[],,,,,"[{""measure_title"": ""ORR According to Immune-related Response Criteria (irRC) as Assessed by Investigator in Melanoma Participants (Parts B Plus D)"", ""units"": ""Percentage of Participants"", ""param"": ""Number"", ""dispersion"": ""95% Confidence Interval"", ""values"": [{""group_id"": ""O7"", ""value"": ""35.2"", ""lower"": ""27.9"", ""upper"": ""43.1""}]}]",Percentage of Participants,[],,,[],,,,,,,,,,O7,MEL: Pembrolizumab 2 mg/kg Q3W (Parts B+D),"Participants received pembrolizumab IV at a dose of 2 mg/kg Q2W. After Amendment 3, participants received dosing Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data.",mel pembrolizumab 2 mg kg q3w parts b d,participants received pembrolizumab iv at a dose of 2 mg kg q2w after amendment 3 participants received dosing q3w after amendment 10 all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab iv q3w based on analysis of safety and efficacy data,NCT01295827_A7,MEL: Pembrolizumab 2 mg/kg Q3W (Parts B+D),"Participants received pembrolizumab IV at a dose of 2 mg/kg Q2W. After Amendment 3, participants received dosing Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data.",mel pembrolizumab 2 mg kg q3w parts b d,participants received pembrolizumab iv at a dose of 2 mg kg q2w after amendment 3 participants received dosing q3w after amendment 10 all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab iv q3w based on analysis of safety and efficacy data,precise_title,100,100,,"[{""arm_id"": ""NCT01295827_A7"", ""arm_group_title_raw"": ""MEL: Pembrolizumab 2 mg/kg Q3W (Parts B+D)"", ""arm_group_desc_raw"": ""Participants received pembrolizumab IV at a dose of 2 mg/kg Q2W. After Amendment 3, participants received dosing Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT01295827_A8"", ""arm_group_title_raw"": ""MEL: Pembrolizumab 10 mg/kg Q3W (Parts B+D)"", ""arm_group_desc_raw"": ""Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W. After Amendment 7, participants received dosing Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data."", ""title_score"": 96, ""desc_score"": 99}, {""arm_id"": ""NCT01295827_A10"", ""arm_group_title_raw"": ""NSCLC: Pembrolizumab 2 mg/kg Q3W (Part F)"", ""arm_group_desc_raw"": ""Participants received pembrolizumab IV at a dose of 2 mg/kg Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data."", ""title_score"": 86, ""desc_score"": 90}]"
NCT01295827,Pembrolizumab,NCT01295827_A8,ORR According to Immune-related Response Criteria (irRC) as Assessed by Investigator in Melanoma Participants (Parts B Plus D),Key Secondary,,[],,,,,"[{""measure_title"": ""ORR According to Immune-related Response Criteria (irRC) as Assessed by Investigator in Melanoma Participants (Parts B Plus D)"", ""units"": ""Percentage of Participants"", ""param"": ""Number"", ""dispersion"": ""95% Confidence Interval"", ""values"": [{""group_id"": ""O8"", ""value"": ""39.9"", ""lower"": ""34.5"", ""upper"": ""45.6""}]}]",Percentage of Participants,[],,,[],,,,,,,,,,O8,MEL: Pembrolizumab 10 mg/kg Q3W (Parts B+D),"Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W. After Amendment 7, participants received dosing Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data.",mel pembrolizumab 10 mg kg q3w parts b d,participants received pembrolizumab iv at a dose of 10 mg kg q2w after amendment 7 participants received dosing q3w after amendment 10 all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab iv q3w based on analysis of safety and efficacy data,NCT01295827_A8,MEL: Pembrolizumab 10 mg/kg Q3W (Parts B+D),"Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W. After Amendment 7, participants received dosing Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data.",mel pembrolizumab 10 mg kg q3w parts b d,participants received pembrolizumab iv at a dose of 10 mg kg q2w after amendment 7 participants received dosing q3w after amendment 10 all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab iv q3w based on analysis of safety and efficacy data,precise_title,100,100,,"[{""arm_id"": ""NCT01295827_A8"", ""arm_group_title_raw"": ""MEL: Pembrolizumab 10 mg/kg Q3W (Parts B+D)"", ""arm_group_desc_raw"": ""Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W. After Amendment 7, participants received dosing Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT01295827_A7"", ""arm_group_title_raw"": ""MEL: Pembrolizumab 2 mg/kg Q3W (Parts B+D)"", ""arm_group_desc_raw"": ""Participants received pembrolizumab IV at a dose of 2 mg/kg Q2W. After Amendment 3, participants received dosing Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data."", ""title_score"": 96, ""desc_score"": 99}, {""arm_id"": ""NCT01295827_A10"", ""arm_group_title_raw"": ""NSCLC: Pembrolizumab 2 mg/kg Q3W (Part F)"", ""arm_group_desc_raw"": ""Participants received pembrolizumab IV at a dose of 2 mg/kg Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data."", ""title_score"": 82, ""desc_score"": 89}]"
NCT01295827,Pembrolizumab,NCT01295827_A9,ORR According to Immune-related Response Criteria (irRC) as Assessed by Investigator in Melanoma Participants (Parts B Plus D),Key Secondary,,[],,,,,"[{""measure_title"": ""ORR According to Immune-related Response Criteria (irRC) as Assessed by Investigator in Melanoma Participants (Parts B Plus D)"", ""units"": ""Percentage of Participants"", ""param"": ""Number"", ""dispersion"": ""95% Confidence Interval"", ""values"": [{""group_id"": ""O9"", ""value"": ""45.6"", ""lower"": ""38.1"", ""upper"": ""53.1""}]}]",Percentage of Participants,[],,,[],,,,,,,,,,O9,MEL: Pembrolizumab 10 mg/kg Q2W (Part B),"Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data.",mel pembrolizumab 10 mg kg q2w part b,participants received pembrolizumab iv at a dose of 10 mg kg q2w after amendment 10 all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab iv q3w based on analysis of safety and efficacy data,NCT01295827_A9,MEL: Pembrolizumab 10 mg/kg Q2W (Part B),"Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data.",mel pembrolizumab 10 mg kg q2w part b,participants received pembrolizumab iv at a dose of 10 mg kg q2w after amendment 10 all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab iv q3w based on analysis of safety and efficacy data,precise_title,100,100,,"[{""arm_id"": ""NCT01295827_A9"", ""arm_group_title_raw"": ""MEL: Pembrolizumab 10 mg/kg Q2W (Part B)"", ""arm_group_desc_raw"": ""Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT01295827_A12"", ""arm_group_title_raw"": ""NSCLC: Pembrolizumab 10 mg/kg Q2W (Part F)"", ""arm_group_desc_raw"": ""Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data."", ""title_score"": 89, ""desc_score"": 100}, {""arm_id"": ""NCT01295827_A11"", ""arm_group_title_raw"": ""NSCLC: Pembrolizumab 10 mg/kg Q3W (Parts C+F)"", ""arm_group_desc_raw"": ""Participants received pembrolizumab IV at a dose of 10 mg/kg Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data."", ""title_score"": 84, ""desc_score"": 100}]"
NCT01295827,Pembrolizumab,NCT01295827_A10,ORR According to Immune-related Response Criteria (irRC) as Assessed by Investigator in Melanoma Participants (Parts B Plus D),Key Secondary,,[],,,,,[],,[],,,[],,,,,,,,,,O10,NSCLC: Pembrolizumab 2 mg/kg Q3W (Part F),"Participants received pembrolizumab IV at a dose of 2 mg/kg Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data.",nsclc pembrolizumab 2 mg kg q3w part f,participants received pembrolizumab iv at a dose of 2 mg kg q3w after amendment 10 all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab iv q3w based on analysis of safety and efficacy data,NCT01295827_A10,NSCLC: Pembrolizumab 2 mg/kg Q3W (Part F),"Participants received pembrolizumab IV at a dose of 2 mg/kg Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data.",nsclc pembrolizumab 2 mg kg q3w part f,participants received pembrolizumab iv at a dose of 2 mg kg q3w after amendment 10 all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab iv q3w based on analysis of safety and efficacy data,precise_title,100,100,,"[{""arm_id"": ""NCT01295827_A10"", ""arm_group_title_raw"": ""NSCLC: Pembrolizumab 2 mg/kg Q3W (Part F)"", ""arm_group_desc_raw"": ""Participants received pembrolizumab IV at a dose of 2 mg/kg Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT01295827_A11"", ""arm_group_title_raw"": ""NSCLC: Pembrolizumab 10 mg/kg Q3W (Parts C+F)"", ""arm_group_desc_raw"": ""Participants received pembrolizumab IV at a dose of 10 mg/kg Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data."", ""title_score"": 92, ""desc_score"": 99}, {""arm_id"": ""NCT01295827_A7"", ""arm_group_title_raw"": ""MEL: Pembrolizumab 2 mg/kg Q3W (Parts B+D)"", ""arm_group_desc_raw"": ""Participants received pembrolizumab IV at a dose of 2 mg/kg Q2W. After Amendment 3, participants received dosing Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data."", ""title_score"": 86, ""desc_score"": 90}]"
NCT01295827,Pembrolizumab,NCT01295827_A11,ORR According to Immune-related Response Criteria (irRC) as Assessed by Investigator in Melanoma Participants (Parts B Plus D),Key Secondary,,[],,,,,[],,[],,,[],,,,,,,,,,O11,NSCLC: Pembrolizumab 10 mg/kg Q3W (Parts C+F),"Participants received pembrolizumab IV at a dose of 10 mg/kg Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data.",nsclc pembrolizumab 10 mg kg q3w parts c f,participants received pembrolizumab iv at a dose of 10 mg kg q3w after amendment 10 all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab iv q3w based on analysis of safety and efficacy data,NCT01295827_A11,NSCLC: Pembrolizumab 10 mg/kg Q3W (Parts C+F),"Participants received pembrolizumab IV at a dose of 10 mg/kg Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data.",nsclc pembrolizumab 10 mg kg q3w parts c f,participants received pembrolizumab iv at a dose of 10 mg kg q3w after amendment 10 all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab iv q3w based on analysis of safety and efficacy data,precise_title,100,100,,"[{""arm_id"": ""NCT01295827_A11"", ""arm_group_title_raw"": ""NSCLC: Pembrolizumab 10 mg/kg Q3W (Parts C+F)"", ""arm_group_desc_raw"": ""Participants received pembrolizumab IV at a dose of 10 mg/kg Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT01295827_A12"", ""arm_group_title_raw"": ""NSCLC: Pembrolizumab 10 mg/kg Q2W (Part F)"", ""arm_group_desc_raw"": ""Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data."", ""title_score"": 94, ""desc_score"": 100}, {""arm_id"": ""NCT01295827_A9"", ""arm_group_title_raw"": ""MEL: Pembrolizumab 10 mg/kg Q2W (Part B)"", ""arm_group_desc_raw"": ""Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data."", ""title_score"": 84, ""desc_score"": 100}]"
NCT01295827,Pembrolizumab,NCT01295827_A12,ORR According to Immune-related Response Criteria (irRC) as Assessed by Investigator in Melanoma Participants (Parts B Plus D),Key Secondary,,[],,,,,[],,[],,,[],,,,,,,,,,O12,NSCLC: Pembrolizumab 10 mg/kg Q2W (Part F),"Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data.",nsclc pembrolizumab 10 mg kg q2w part f,participants received pembrolizumab iv at a dose of 10 mg kg q2w after amendment 10 all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab iv q3w based on analysis of safety and efficacy data,NCT01295827_A12,NSCLC: Pembrolizumab 10 mg/kg Q2W (Part F),"Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data.",nsclc pembrolizumab 10 mg kg q2w part f,participants received pembrolizumab iv at a dose of 10 mg kg q2w after amendment 10 all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab iv q3w based on analysis of safety and efficacy data,precise_title,100,100,,"[{""arm_id"": ""NCT01295827_A12"", ""arm_group_title_raw"": ""NSCLC: Pembrolizumab 10 mg/kg Q2W (Part F)"", ""arm_group_desc_raw"": ""Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT01295827_A11"", ""arm_group_title_raw"": ""NSCLC: Pembrolizumab 10 mg/kg Q3W (Parts C+F)"", ""arm_group_desc_raw"": ""Participants received pembrolizumab IV at a dose of 10 mg/kg Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data."", ""title_score"": 94, ""desc_score"": 100}, {""arm_id"": ""NCT01295827_A9"", ""arm_group_title_raw"": ""MEL: Pembrolizumab 10 mg/kg Q2W (Part B)"", ""arm_group_desc_raw"": ""Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data."", ""title_score"": 89, ""desc_score"": 100}]"
